Ovarian Neoplasms
Conditions
Keywords
Ovarian Cancer, Homologous Recombination Deficiency (HRD), Interval debulking surgery (IDS), Niraparib, Paclitaxel, Carboplatin
Brief summary
The goal of the study is to learn whether Niraparib or Platinum-Taxane Doublet chemotherapy is better in treating participants with Homologous Recombination Deficient (HRd) Stage III/IV Ovarian Cancer (OC). This study is a sub-study of the Master protocol -OPAL (NCT03574779)
Interventions
DRUGNiraparib
Niraparib will be administered
DRUGCarboplatin
Carboplatin will be administered
DRUGPaclitaxel
Paclitaxel will be administered
Sponsors
Tesaro, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participant has newly diagnosed Stage III or IV ovarian, fallopian tube, or primary peritoneal cancer according to the International Federation of Gynecology and Obstetrics staging criteria. * Participants must provide sufficient tumor tissue at Prescreening and agree to undergo a central HRD tumor testing using a fully validated assay. The participants must be HRd as per central HRD tumor testing result for eligibility. 1. Participants with a documented germline breast cancer susceptibility gene (BRCA) 1/2 deleterious or suspected deleterious mutations by Sponsor's permitted test (e.g., BRACAnalysis CDx) may be allowed to enroll prior to receiving the central test results, provided all inclusion criteria are met. However, tumor sample submitted by these participants will still be required for central HRD confirmation. The list of Sponsor's permitted tests will be provided by the Sponsor. 2. All participants must agree to provide tumor tissue collected from IDS. 3. Participant must provide 2 formalin-fixed paraffin-embedded tissue blocks (or slides if blocks are not available) with sufficient tumor content (as confirmed by the Sponsor's designated central and/or testing laboratory) for central HRD testing at Prescreening and for exploratory biomarker testing at Prescreening or Screening. If sufficient tumor tissue is provided at Prescreening, participants do not need to provide additional tissue at Screening. * Participant must have completed 1 run-in cycle of carboplatin-paclitaxel and not experienced disease progression after this treatment. Completion is defined as receiving ≥50% of the prescribed dose of therapy within 5 weeks. * Participant must not have known contraindication or uncontrolled hypersensitivity to carboplatin and paclitaxel and their excipients and no known pre-existing conditions that would preclude treatment with these agents. * Participant must not have known contraindication or uncontrolled hypersensitivity to niraparib and its excipients. * Participant must not have symptomatic ascites or pleural effusions as defined by the following criterion: presence of fluid in the abdominal or pleural cavities requiring removal within 1 week prior to signing the informed consent. * Participant must agree to complete Patient-reported outcome (PRO) and work productivity questionnaires throughout the study.
Exclusion criteria
* Participant has low-grade or Grade 1 epithelial Ovarian Cancer (OC) or mucinous, germ cell, transitional cell, carcinosarcoma, or undifferentiated tumor. * Participant has contraindications to surgery. * Participant has a bowel obstruction by clinical symptoms or Computed tomography (CT) scan, subocclusive mesenteric disease, abdominal or gastrointestinal fistula, gastrointestinal perforation, or intra-abdominal abscess. * Participant has any known history or current diagnosis of Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). * Participant is at increased bleeding risk due to concurrent conditions (e.g., major injuries or major surgery within the past 28 days prior to the start of study treatment and/or history of hemorrhagic stroke, transient ischemic attack, subarachnoid hemorrhage, or clinically significant hemorrhage within the past 3 months). * Participant is immunocompromised. Participants with splenectomy are allowed. Participants with known Human immunodeficiency virus (HIV) are allowed if they meet all of the following criteria: 1. Cluster of differentiation 4-positive T cell count ≥350/μL and viral load \<400 copies/mL 2. No history of Acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections within 12 months prior to enrollment 3. No history of HIV-associated malignancy for the past 5 years 4. Concurrent antiretroviral therapy as per the most current National Institutes of Health Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV started \>4 weeks prior to study enrollment * Participant received prior treatment for high-grade non-mucinous epithelial ovarian, fallopian tube, or peritoneal cancer (e.g., prior surgery, immunotherapy, anticancer therapy \[with the exception of 1 run-in cycle of carboplatin-paclitaxel\], or radiation therapy). * Participant has an active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy is not considered a form of systemic therapy (e.g., thyroid hormone or insulin). * Participant is unable to swallow orally administered medication or has a gastrointestinal disorder likely to interfere with absorption of the study medication. * Participant received whole blood transfusions in the 2 weeks prior to entry to the study (packed red blood cells and platelet transfusions are acceptable outside of 2 weeks prior to treatment).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pre-Interval Debulking Surgery (IDS) Unconfirmed Overall Response Rate (ORR) | Up to approximately 102 weeks | Pre-IDS unconfirmed ORR is defined as the percentage of participants with unconfirmed complete or partial response on study treatment pre-IDS as assessed per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by the Investigator. Complete Response (CR) is defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) | Up to approximately 154 weeks | PFS is defined as the time from the date of treatment randomization to the date of first documentation of disease progression (PD) per RECIST v1.1 or death by any cause, whichever occurs first, as determined by the Investigator. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm. |
| Overall Survival (OS) | Up to approximately 154 weeks | OS is defined as the time from the date of treatment randomization to the date of death by any cause. |
| Time to First Subsequent Treatment (TFST) | Up to approximately 154 weeks | TFST is defined as the time from the date of treatment randomization to the date of first subsequent anticancer therapy or death. |
| Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Baseline (Predose), Day 8 and 15 of Cycle 1; Day 1, 8 and 15 of Cycle 2 and Cycle 3; Pre-IDS Evaluation, and End of Treatment (Up to approximately 154 weeks). | The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants of cancer clinical studies. It characterizes the frequency and severity of adverse events using a standardized scoring system. Responses include 0 (never OR none OR Not at all); 1 (Rarely OR Mild OR A little bit); 2 (Occasionally OR Moderate OR Somewhat); 3 (Frequently OR Severe OR Quite a bit) and 4 (almost constantly OR very severe OR Very much), with a higher score indicating a higher frequency and severity of adverse events. |
| Number of Participants With Cancer Antigen (CA)-125 Progression by Gynecological Cancer InterGroup (GCIG) CA-125 Response Criteria | At week 24 | Serum samples were collected to assess CA-125 progression based on the GCIG CA-125 response criteria, which is defined as follows: Criteria 1 - For participants with elevated CA-125 levels pre-treatment that reduced to the normal range during the study, progression is defined as CA-125 ≥2× Upper limit of normal (ULN) on 2 occasions at least 1 week apart.; Criteria 2 - For participants with elevated CA-125 levels pre-treatment that did not reduce to the normal range during the study, progression is defined as CA-125 ≥2× the nadir value on 2 occasions at least 1 week apart.; Criteria 3 - For participants with CA-125 levels in the normal range pre-treatment, progression is defined as CA-125 ≥2× ULN on 2 occasions at least 1 week apart. |
| Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Baseline (Predose), Day 1 of Cycle 2 and Cycle 3; Pre-IDS Evaluation, and End of Treatment (Up to approximately 154 weeks). | EORTC IL136 includes items from the EORTC QLQ-C30, a 30-item survey assessing health-related quality of life (HRQoL) in cancer patients, featuring 5 functional scales, 3 symptom scales, 6 single items, and a global health status/HRQoL scale. Functional and symptom scales/items are rated on 4-point scale with options Not at all, A little, Quite a bit, and Very much. 2 items measuring global health status/quality of life use a 7-point scale ranging from 1 (Very Poor) to 7 (Excellent). Each item has a specific scoring system, and scores were transformed to a 0-100 scale, where higher scores on functional scales and global health status/HRQoL scale indicate better functioning or quality of life, while higher scores on symptom scales/items indicate greater symptom burden. Baseline is defined as the latest assessment with a non-missing value prior to Cycle 1 Day 1 (C1D1), including those from unscheduled visits. |
| Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Baseline (Predose), Day 1 of Cycle 2 and Cycle 3; Pre-IDS Evaluation, and End of Treatment (Up to approximately 154 weeks). | The OC module (QLQ-OV28) supplements the QLQ-C30 and was designed for participants with local or advanced disease who receive treatment by surgery with or without chemotherapy. It consists of 28 items including 3 functional scales (body image, sexuality, attitude to disease/treatment burden) and 5 symptom scales/items (abdominal/gastrointestinal symptoms, peripheral neuropathy, hormonal/menopausal symptoms, other chemotherapy side effects, and hair loss). A subset of 9 questions will be utilized for this cohort, referred to as the EORTC IL137. The scoring approach is identical to the EORTC QLQ-C30. Scores are transformed to a 0-100 scale, where higher functional scale scores indicate better functioning, and higher symptom scale scores indicate greater symptom burden. Baseline is defined as the latest assessment with a non-missing value prior to C1D1, including unscheduled visits. |
| Number of Participants With Treatment Emergent (TE) Non-serious Adverse Events (Non-SAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Adverse Events of Treatment Emergent (TE) Special Interest (AESIs) by Severity | Up to approximately 154 weeks | An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, is life threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, is a congenital anomaly/birth defect, other situations and is associated with liver injury or impaired liver function. SAEs are subsets of AEs. TEAE is an event that emerged during treatment having been absent pretreatment or worsened relative to the pretreatment state. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system. |
| Number of Participants With Dose Modification Due to TEAEs | Up to approximately 154 weeks | An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is an event that emerged during treatment having been absent pretreatment or worsened relative to the pretreatment state. Number of participants with dose modifications : permanent discontinuation, dose reduction and treatment interruption/delay due to AEs is summarized. |
| Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Baseline (Predose), Day 8 and 15 of Cycle 1; Day 1, 8, and 15 of Cycle 2 and Cycle 3; Pre-IDS Evaluation, and End of Treatment (Up to approximately 154 weeks) | The FACT-GP5 item is a single item from the FACT-G that assesses how bothersome the side effects of treatment are for participants with cancer. It evaluates the extent to which side effects of treatment are bothersome for cancer participants. This outcome is measured using a 5-category response scale, where responses include 0=Not at all, 1=A little bit, 2=Somewhat, 3=Quite a bit, and 4=Very much. A higher score on this measure indicates that the participant experiences a greater level of bother from the side effects of treatment. |
Countries
Canada, Spain, United States
Participant flow
Pre-assignment details
This study is a sub study of the master protocol (NCT03574779).
Participants by arm
| Arm | Count |
|---|---|
| Platinum-taxane Participants with ovarian cancer received platinum-taxane doublet chemotherapy as solution for intravenous infusion for three 21-day cycles (Cycles 1, 2 and 3). After 3 cycles of treatment, the participants underwent interval debulking surgery (IDS) with recovery period of up to 6 weeks. After IDS, all participants received another three 21-day cycles of platinum-taxane doublet chemotherapy (Cycles 4, 5, and 6), with the last cycle (Cycle 6) being optional followed by niraparib maintenance treatment for up to 36 months or until an adverse event (AE), progression of disease (PD) per RECIST v1.1. | 17 |
| Niraparib Participants with ovarian cancer received 100 milligram (mg) Niraparib capsules orally for three 21-day cycles (Cycles 1, 2 and 3). After 3 cycles of treatment, the participants underwent IDS with recovery period of up to 6 weeks. After IDS, all participants received three 21-day cycles of platinum-taxane doublet chemotherapy (Cycles 4, 5, and 6), with the last cycle (Cycle 6) being optional, followed by niraparib maintenance treatment for up to 36 months or until an AE, PD per RECIST v1.1. Participants with screening actual body weight greater than or equal (≥) to 77 kg and screening platelets count ≥ 150000 cells per microliter were administered 300 mg of Niraparib. Participants with screening actual body weight less than 77 kg or screening platelets count less than 150000 cells per microliter were administered 200 mg of niraparib. | 19 |
| Total | 36 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Death | 4 | 4 |
| Overall Study | Participant discontinued due to relocation to a long-term care facility | 0 | 1 |
| Overall Study | Participant removed due to non-compliance | 0 | 1 |
| Overall Study | Physician Decision | 1 | 1 |
| Overall Study | Study terminated by sponsor | 12 | 10 |
| Overall Study | Withdrawal by Subject | 0 | 2 |
Baseline characteristics
| Characteristic | Niraparib | Total | Platinum-taxane |
|---|---|---|---|
| Age, Continuous | 58.4 YEARS STANDARD_DEVIATION 12.26 | 59.6 YEARS STANDARD_DEVIATION 12.82 | 61.0 YEARS STANDARD_DEVIATION 13.67 |
| Race/Ethnicity, Customized Hispanic or Latino | 3 Participants | 4 Participants | 1 Participants |
| Race/Ethnicity, Customized Not Hispanic or Latino | 16 Participants | 32 Participants | 16 Participants |
| Sex: Female, Male Female | 19 Participants | 36 Participants | 17 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 4 / 17 | 4 / 19 |
| other Total, other adverse events | 17 / 17 | 19 / 19 |
| serious Total, serious adverse events | 4 / 17 | 2 / 19 |
Outcome results
Primary
Pre-Interval Debulking Surgery (IDS) Unconfirmed Overall Response Rate (ORR)
Pre-IDS unconfirmed ORR is defined as the percentage of participants with unconfirmed complete or partial response on study treatment pre-IDS as assessed per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by the Investigator. Complete Response (CR) is defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters
Time frame: Up to approximately 102 weeks
Population: Intent-to-Treat population included all randomized participants whether or not randomized treatment was administered.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Platinum-taxane | Pre-Interval Debulking Surgery (IDS) Unconfirmed Overall Response Rate (ORR) | 70.6 Percentage of Participants |
| Niraparib | Pre-Interval Debulking Surgery (IDS) Unconfirmed Overall Response Rate (ORR) | 31.6 Percentage of Participants |
80% CI: [-56.8, -17.7]
Secondary
Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire
EORTC IL136 includes items from the EORTC QLQ-C30, a 30-item survey assessing health-related quality of life (HRQoL) in cancer patients, featuring 5 functional scales, 3 symptom scales, 6 single items, and a global health status/HRQoL scale. Functional and symptom scales/items are rated on 4-point scale with options Not at all, A little, Quite a bit, and Very much. 2 items measuring global health status/quality of life use a 7-point scale ranging from 1 (Very Poor) to 7 (Excellent). Each item has a specific scoring system, and scores were transformed to a 0-100 scale, where higher scores on functional scales and global health status/HRQoL scale indicate better functioning or quality of life, while higher scores on symptom scales/items indicate greater symptom burden. Baseline is defined as the latest assessment with a non-missing value prior to Cycle 1 Day 1 (C1D1), including those from unscheduled visits.
Time frame: Baseline (Predose), Day 1 of Cycle 2 and Cycle 3; Pre-IDS Evaluation, and End of Treatment (Up to approximately 154 weeks).
Population: Intent to Treat Population is included as the Overall Number of Participants Analyzed. 'Number Analyzed' refers to participants evaluable at the specified time points. The 0 participants analyzed represents that data was not collected or available for analysis at that particular time point for the respective Arms/Groups.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Need Help Eating Dressing Washing, CFB to CYCLE 2 DAY 1 | 0.00 Scores on scale | Standard Deviation 0 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Trouble Doing Strenuous Activity, CFB to Pre-IDS EVALUATION | -7.14 Scores on scale | Standard Deviation 19.298 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Need Help Eating Dressing Washing, CFB to CYCLE 3 DAY 1 | 0.00 Scores on scale | Standard Deviation 0 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Physical Functioning Scale, CFB to CYCLE 3 DAY 1 | 1.53 Scores on scale | Standard Deviation 12.702 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Need Help Eating Dressing Washing, CFB to Pre-IDS EVALUATION | 0.00 Scores on scale | Standard Deviation 0 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Rate Your Overall Quality of Life, CFB to CYCLE 3 DAY 1 | 5.56 Scores on scale | Standard Deviation 19.245 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Have Trouble Taking a Long Walk, CFB to CYCLE 2 DAY 1 | 0.00 Scores on scale | Standard Deviation 21.082 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Social Functioning Scale, CFB to CYCLE 2 DAY 1 | 13.64 Scores on scale | Standard Deviation 27.707 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Rate Your Overall Health, CFB to CYCLE 2 DAY 1 | -1.52 Scores on scale | Standard Deviation 22.918 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Social Functioning Scale, CFB to CYCLE 3 DAY 1 | 13.89 Scores on scale | Standard Deviation 30.841 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Have Trouble Taking a Long Walk, CFB to CYCLE 3 DAY 1 | 13.89 Scores on scale | Standard Deviation 30.011 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Social Functioning Scale, CFB to Pre-IDS EVALUATION | 7.14 Scores on scale | Standard Deviation 27.514 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Rate Your Overall Quality of Life, CFB to Pre-IDS EVALUATION | -3.57 Scores on scale | Standard Deviation 21.857 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Have Trouble Taking a Long Walk, CFB to Pre-IDS EVALUATION | 4.76 Scores on scale | Standard Deviation 22.1 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Cond Interfere With Family Life, CFB to CYCLE 2 DAY 1 | 18.18 Scores on scale | Standard Deviation 31.14 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Global Health Status/QoL, CFB to Pre-IDS EVALUATION | -4.17 Scores on scale | Standard Deviation 22.349 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Cond Interfere With Family Life, CFB to CYCLE 3 DAY 1 | 13.89 Scores on scale | Standard Deviation 33.207 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Rate Your Overall Health, CFB to CYCLE 3 DAY 1 | 9.72 Scores on scale | Standard Deviation 16.603 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Cond Interfere With Family Life, CFB to Pre-IDS EVALUATION | 14.29 Scores on scale | Standard Deviation 36.314 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Have Trouble Taking Short Walk, CFB to CYCLE 2 DAY 1 | 6.06 Scores on scale | Standard Deviation 20.101 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Global Health Status/QoL, CFB to CYCLE 2 DAY 1 | 0.00 Scores on scale | Standard Deviation 19.365 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Cond Interfere Social Activity, CFB to CYCLE 2 DAY 1 | 9.09 Scores on scale | Standard Deviation 30.151 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Have Trouble Taking Short Walk, CFB to CYCLE 3 DAY 1 | 0.00 Scores on scale | Standard Deviation 33.333 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Cond Interfere Social Activity, CFB to CYCLE 3 DAY 1 | 13.89 Scores on scale | Standard Deviation 30.011 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Physical Functioning Scale, CFB to Pre-IDS EVALUATION | -1.43 Scores on scale | Standard Deviation 10.838 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Cond Interfere Social Activity, CFB to Pre-IDS EVALUATION | 0.00 Scores on scale | Standard Deviation 26.149 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Have Trouble Taking Short Walk, CFB to Pre-IDS EVALUATION | -4.76 Scores on scale | Standard Deviation 17.817 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Rate Your Overall Health, CFB to Pre-IDS EVALUATION | -4.76 Scores on scale | Standard Deviation 23.956 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Dyspnea Symptom Scale, CFB to CYCLE 2 DAY 1 | -3.03 Scores on scale | Standard Deviation 10.05 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Physical Functioning Scale, CFB to CYCLE 2 DAY 1 | 0.61 Scores on scale | Standard Deviation 13.15 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Dyspnea Symptom Scale, CFB to CYCLE 3 DAY 1 | 0.00 Scores on scale | Standard Deviation 14.213 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Stay in Bed or Chair During Day, CFB to CYCLE 2 DAY 1 | -3.03 Scores on scale | Standard Deviation 17.979 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Dyspnea Symptom Scale, CFB to Pre-IDS EVALUATION | 0.00 Scores on scale | Standard Deviation 13.074 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Trouble Doing Strenuous Activity, CFB to CYCLE 2 DAY 1 | 0.00 Scores on scale | Standard Deviation 21.082 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Stay in Bed or Chair During Day, CFB to CYCLE 3 DAY 1 | -2.78 Scores on scale | Standard Deviation 22.285 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Were You Short of Breath, CFB to CYCLE 2 DAY 1 | -3.03 Scores on scale | Standard Deviation 10.05 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Global Health Status/QoL, CFB to CYCLE 3 DAY 1 | 7.64 Scores on scale | Standard Deviation 16.46 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Were You Short of Breath, CFB to CYCLE 3 DAY 1 | 0.00 Scores on scale | Standard Deviation 14.213 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Stay in Bed or Chair During Day, CFB to Pre-IDS EVALUATION | 0.00 Scores on scale | Standard Deviation 18.49 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Were You Short of Breath, CFB to Pre-IDS EVALUATION | 0.00 Scores on scale | Standard Deviation 13.074 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Trouble Doing Strenuous Activity, CFB to CYCLE 3 DAY 1 | -2.78 Scores on scale | Standard Deviation 9.623 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Rate Your Overall Quality of Life, CFB to CYCLE 2 DAY 1 | 1.52 Scores on scale | Standard Deviation 18.936 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Cond Interfere With Family Life, CFB to Pre-IDS EVALUATION | -5.56 Scores on scale | Standard Deviation 38.968 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Cond Interfere With Family Life, CFB to END OF TREATMENT | -6.67 Scores on scale | Standard Deviation 27.889 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Cond Interfere Social Activity, CFB to CYCLE 2 DAY 1 | 9.09 Scores on scale | Standard Deviation 33.635 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Cond Interfere Social Activity, CFB to CYCLE 3 DAY 1 | 11.11 Scores on scale | Standard Deviation 28.868 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Cond Interfere Social Activity, CFB to Pre-IDS EVALUATION | 22.22 Scores on scale | Standard Deviation 17.213 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Cond Interfere Social Activity, CFB to END OF TREATMENT | 13.33 Scores on scale | Standard Deviation 18.257 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Dyspnea Symptom Scale, CFB to CYCLE 2 DAY 1 | 3.03 Scores on scale | Standard Deviation 17.979 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Dyspnea Symptom Scale, CFB to CYCLE 3 DAY 1 | 0.00 Scores on scale | Standard Deviation 28.868 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Dyspnea Symptom Scale, CFB to Pre-IDS EVALUATION | 0.00 Scores on scale | Standard Deviation 47.14 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Dyspnea Symptom Scale, CFB to END OF TREATMENT | 6.67 Scores on scale | Standard Deviation 27.889 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Were You Short of Breath, CFB to CYCLE 2 DAY 1 | 3.03 Scores on scale | Standard Deviation 17.979 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Were You Short of Breath, CFB to CYCLE 3 DAY 1 | 0.00 Scores on scale | Standard Deviation 28.868 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Were You Short of Breath, CFB to Pre-IDS EVALUATION | 0.00 Scores on scale | Standard Deviation 47.14 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Global Health Status/QoL, CFB to CYCLE 3 DAY 1 | 10.19 Scores on scale | Standard Deviation 38.814 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Were You Short of Breath, CFB to END OF TREATMENT | 6.67 Scores on scale | Standard Deviation 27.889 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Global Health Status/QoL, CFB to Pre-IDS EVALUATION | 9.72 Scores on scale | Standard Deviation 27.597 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Physical Functioning Scale, CFB to CYCLE 3 DAY 1 | 10.37 Scores on scale | Standard Deviation 16.025 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Global Health Status/QoL, CFB to CYCLE 2 DAY 1 | 3.79 Scores on scale | Standard Deviation 27.224 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Global Health Status/QoL, CFB to END OF TREATMENT | -23.33 Scores on scale | Standard Deviation 23.863 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Rate Your Overall Health, CFB to CYCLE 2 DAY 1 | 4.55 Scores on scale | Standard Deviation 27.979 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Rate Your Overall Health, CFB to CYCLE 3 DAY 1 | 9.26 Scores on scale | Standard Deviation 40.062 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Rate Your Overall Health, CFB to Pre-IDS EVALUATION | 11.11 Scores on scale | Standard Deviation 29.187 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Rate Your Overall Health, CFB to END OF TREATMENT | -20.00 Scores on scale | Standard Deviation 18.257 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Rate Your Overall Quality of Life, CFB to CYCLE 2 DAY 1 | 3.03 Scores on scale | Standard Deviation 28.692 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Rate Your Overall Quality of Life, CFB to CYCLE 3 DAY 1 | 11.11 Scores on scale | Standard Deviation 38.188 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Rate Your Overall Quality of Life, CFB to Pre-IDS EVALUATION | 8.33 Scores on scale | Standard Deviation 27.386 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Rate Your Overall Quality of Life, CFB to END OF TREATMENT | -26.67 Scores on scale | Standard Deviation 32.489 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Physical Functioning Scale, CFB to CYCLE 2 DAY 1 | 7.27 Scores on scale | Standard Deviation 12.808 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Physical Functioning Scale, CFB to Pre-IDS EVALUATION | 14.44 Scores on scale | Standard Deviation 20.403 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Physical Functioning Scale, CFB to END OF TREATMENT | -9.33 Scores on scale | Standard Deviation 17.385 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Trouble Doing Strenuous Activity, CFB to CYCLE 2 DAY 1 | 3.03 Scores on scale | Standard Deviation 27.707 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Trouble Doing Strenuous Activity, CFB to CYCLE 3 DAY 1 | 22.22 Scores on scale | Standard Deviation 23.57 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Trouble Doing Strenuous Activity, CFB to Pre-IDS EVALUATION | 22.22 Scores on scale | Standard Deviation 34.427 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Trouble Doing Strenuous Activity, CFB to END OF TREATMENT | 0.00 Scores on scale | Standard Deviation 33.333 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Have Trouble Taking a Long Walk, CFB to CYCLE 2 DAY 1 | 21.21 Scores on scale | Standard Deviation 30.814 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Have Trouble Taking a Long Walk, CFB to CYCLE 3 DAY 1 | 11.11 Scores on scale | Standard Deviation 28.868 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Have Trouble Taking a Long Walk, CFB to Pre-IDS EVALUATION | 22.22 Scores on scale | Standard Deviation 34.427 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Have Trouble Taking a Long Walk, CFB to END OF TREATMENT | -6.67 Scores on scale | Standard Deviation 14.907 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Have Trouble Taking Short Walk, CFB to CYCLE 2 DAY 1 | 9.09 Scores on scale | Standard Deviation 15.57 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Have Trouble Taking Short Walk, CFB to CYCLE 3 DAY 1 | 7.41 Scores on scale | Standard Deviation 14.699 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Have Trouble Taking Short Walk, CFB to Pre-IDS EVALUATION | 16.67 Scores on scale | Standard Deviation 27.889 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Have Trouble Taking Short Walk, CFB to END OF TREATMENT | -13.33 Scores on scale | Standard Deviation 18.257 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Stay in Bed or Chair During Day, CFB to CYCLE 2 DAY 1 | 0.00 Scores on scale | Standard Deviation 25.82 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Stay in Bed or Chair During Day, CFB to CYCLE 3 DAY 1 | 7.41 Scores on scale | Standard Deviation 22.222 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Stay in Bed or Chair During Day, CFB to Pre-IDS EVALUATION | 0.00 Scores on scale | Standard Deviation 21.082 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Stay in Bed or Chair During Day, CFB to END OF TREATMENT | -13.33 Scores on scale | Standard Deviation 18.257 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Need Help Eating Dressing Washing, CFB to CYCLE 2 DAY 1 | 3.03 Scores on scale | Standard Deviation 17.979 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Need Help Eating Dressing Washing, CFB to CYCLE 3 DAY 1 | 3.70 Scores on scale | Standard Deviation 20.031 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Need Help Eating Dressing Washing, CFB to Pre-IDS EVALUATION | 11.11 Scores on scale | Standard Deviation 17.213 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Need Help Eating Dressing Washing, CFB to END OF TREATMENT | -13.33 Scores on scale | Standard Deviation 18.257 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Social Functioning Scale, CFB to CYCLE 2 DAY 1 | 7.58 Scores on scale | Standard Deviation 36.027 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Social Functioning Scale, CFB to CYCLE 3 DAY 1 | 1.85 Scores on scale | Standard Deviation 22.737 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Social Functioning Scale, CFB to Pre-IDS EVALUATION | 8.33 Scores on scale | Standard Deviation 25.276 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Social Functioning Scale, CFB to END OF TREATMENT | 3.33 Scores on scale | Standard Deviation 18.257 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Cond Interfere With Family Life, CFB to CYCLE 2 DAY 1 | 6.06 Scores on scale | Standard Deviation 44.267 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire | Cond Interfere With Family Life, CFB to CYCLE 3 DAY 1 | -7.41 Scores on scale | Standard Deviation 27.778 |
Secondary
Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire
The OC module (QLQ-OV28) supplements the QLQ-C30 and was designed for participants with local or advanced disease who receive treatment by surgery with or without chemotherapy. It consists of 28 items including 3 functional scales (body image, sexuality, attitude to disease/treatment burden) and 5 symptom scales/items (abdominal/gastrointestinal symptoms, peripheral neuropathy, hormonal/menopausal symptoms, other chemotherapy side effects, and hair loss). A subset of 9 questions will be utilized for this cohort, referred to as the EORTC IL137. The scoring approach is identical to the EORTC QLQ-C30. Scores are transformed to a 0-100 scale, where higher functional scale scores indicate better functioning, and higher symptom scale scores indicate greater symptom burden. Baseline is defined as the latest assessment with a non-missing value prior to C1D1, including unscheduled visits.
Time frame: Baseline (Predose), Day 1 of Cycle 2 and Cycle 3; Pre-IDS Evaluation, and End of Treatment (Up to approximately 154 weeks).
Population: Intent to Treat Population is included as the Overall Number of Participants Analyzed. 'Number Analyzed' refers to participants evaluable at the specified time points. The 0 participants analyzed represents that data was not collected or available for analysis at that particular time point for the respective Arms/Groups.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Bloated Feeling Abdomen, CFB to CYCLE 2 DAY 1 | -8.33 Scores on scale | Standard Deviation 35.176 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Troubled Pass Flatulence, CFB to CYCLE 3 DAY 1 | -2.78 Scores on scale | Standard Deviation 22.285 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Felt physically Less Attractive, CFB to CYCLE 3 DAY 1 | -2.78 Scores on scale | Standard Deviation 33.207 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Troubled Pass Flatulence, CFB to Pre-IDS EVALUATION | 7.14 Scores on scale | Standard Deviation 26.726 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Bloated Feeling Abdomen, CFB to CYCLE 3 DAY 1 | 0.00 Scores on scale | Standard Deviation 42.64 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Treatment Burden, CFB to CYCLE 2 DAY 1 | -8.33 Scores on scale | Standard Deviation 32.177 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Felt Full Quick after Begin Eat, CFB to CYCLE 2 DAY 1 | -13.89 Scores on scale | Standard Deviation 22.285 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Bloated Feeling Abdomen, CFB to Pre-IDS EVALUATION | 0.00 Scores on scale | Standard Deviation 29.235 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Felt Full Quick after Begin Eat, CFB to CYCLE 3 DAY 1 | -15.15 Scores on scale | Standard Deviation 22.918 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Disease Burden, CFB to CYCLE 3 DAY 1 | 11.11 Scores on scale | Standard Deviation 25.95 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Felt Full Quick after Begin Eat, CFB to Pre-IDS EVALUATION | -11.90 Scores on scale | Standard Deviation 28.063 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Treatment Burden, CFB to CYCLE 3 DAY 1 | 0.00 Scores on scale | Standard Deviation 24.618 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Change Bowel Habit, CFB to CYCLE 2 DAY 1 | -33.33 Scores on scale | Standard Deviation 34.816 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Acid Indigestion or Heartburn, CFB to CYCLE 2 DAY 1 | 2.78 Scores on scale | Standard Deviation 17.164 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Felt physically Less Attractive, CFB to Pre-IDS EVALUATION | 0.00 Scores on scale | Standard Deviation 18.49 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Acid Indigestion or Heartburn, CFB to CYCLE 3 DAY 1 | 5.56 Scores on scale | Standard Deviation 12.975 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Change Bowel Habit, CFB to CYCLE 3 DAY 1 | -13.89 Scores on scale | Standard Deviation 45.965 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Acid Indigestion or Heartburn, CFB to Pre-IDS EVALUATION | 7.14 Scores on scale | Standard Deviation 14.194 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Treatment Burden, CFB to Pre-IDS EVALUATION | 2.38 Scores on scale | Standard Deviation 27.625 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Change Bowel Habit, CFB to Pre-IDS EVALUATION | -16.67 Scores on scale | Standard Deviation 31.351 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Felt Weak in Your Arms or Legs, CFB to CYCLE 2 DAY 1 | -5.56 Scores on scale | Standard Deviation 19.245 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Disease Burden, CFB to Pre-IDS EVALUATION | 11.90 Scores on scale | Standard Deviation 24.832 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Felt Weak in Your Arms or Legs, CFB to CYCLE 3 DAY 1 | 18.18 Scores on scale | Standard Deviation 34.524 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Disease Burden, CFB to CYCLE 2 DAY 1 | 5.56 Scores on scale | Standard Deviation 19.245 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Felt Weak in Your Arms or Legs, CFB to Pre-IDS EVALUATION | 4.76 Scores on scale | Standard Deviation 34.237 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Troubled Pass Flatulence, CFB to CYCLE 2 DAY 1 | 8.33 Scores on scale | Standard Deviation 25.126 |
| Platinum-taxane | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Felt physically Less Attractive, CFB to CYCLE 2 DAY 1 | -2.78 Scores on scale | Standard Deviation 17.164 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Felt Full Quick after Begin Eat, CFB to Pre-IDS EVALUATION | 5.56 Scores on scale | Standard Deviation 25.092 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Felt Full Quick after Begin Eat, CFB to END OF TREATMENT | -6.67 Scores on scale | Standard Deviation 59.628 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Acid Indigestion or Heartburn, CFB to CYCLE 2 DAY 1 | -3.33 Scores on scale | Standard Deviation 29.187 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Acid Indigestion or Heartburn, CFB to CYCLE 3 DAY 1 | -7.41 Scores on scale | Standard Deviation 32.394 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Acid Indigestion or Heartburn, CFB to Pre-IDS EVALUATION | -11.11 Scores on scale | Standard Deviation 27.217 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Acid Indigestion or Heartburn, CFB to END OF TREATMENT | 6.67 Scores on scale | Standard Deviation 27.889 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Felt Weak in Your Arms or Legs, CFB to CYCLE 2 DAY 1 | -6.67 Scores on scale | Standard Deviation 21.082 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Felt Weak in Your Arms or Legs, CFB to CYCLE 3 DAY 1 | -18.52 Scores on scale | Standard Deviation 33.793 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Felt Weak in Your Arms or Legs, CFB to Pre-IDS EVALUATION | -11.11 Scores on scale | Standard Deviation 34.427 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Felt Weak in Your Arms or Legs, CFB to END OF TREATMENT | 6.67 Scores on scale | Standard Deviation 27.889 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Felt physically Less Attractive, CFB to CYCLE 2 DAY 1 | -3.33 Scores on scale | Standard Deviation 33.148 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Felt physically Less Attractive, CFB to CYCLE 3 DAY 1 | 7.41 Scores on scale | Standard Deviation 52.116 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Felt physically Less Attractive, CFB to Pre-IDS EVALUATION | -16.67 Scores on scale | Standard Deviation 27.889 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Felt physically Less Attractive, CFB to END OF TREATMENT | 13.33 Scores on scale | Standard Deviation 38.006 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Disease Burden, CFB to CYCLE 2 DAY 1 | 10.00 Scores on scale | Standard Deviation 27.442 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Disease Burden, CFB to CYCLE 3 DAY 1 | 14.81 Scores on scale | Standard Deviation 50.308 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Disease Burden, CFB to Pre-IDS EVALUATION | 0.00 Scores on scale | Standard Deviation 42.164 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Disease Burden, CFB to END OF TREATMENT | 13.33 Scores on scale | Standard Deviation 44.721 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Treatment Burden, CFB to CYCLE 2 DAY 1 | 3.33 Scores on scale | Standard Deviation 39.907 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Treatment Burden, CFB to CYCLE 3 DAY 1 | 7.41 Scores on scale | Standard Deviation 32.394 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Treatment Burden, CFB to Pre-IDS EVALUATION | 11.11 Scores on scale | Standard Deviation 27.217 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Treatment Burden, CFB to END OF TREATMENT | 13.33 Scores on scale | Standard Deviation 18.257 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Bloated Feeling Abdomen, CFB to CYCLE 2 DAY 1 | -10.00 Scores on scale | Standard Deviation 41.722 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Bloated Feeling Abdomen, CFB to CYCLE 3 DAY 1 | -14.81 Scores on scale | Standard Deviation 29.397 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Bloated Feeling Abdomen, CFB to Pre-IDS EVALUATION | -5.56 Scores on scale | Standard Deviation 49.065 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Bloated Feeling Abdomen, CFB to END OF TREATMENT | 6.67 Scores on scale | Standard Deviation 43.461 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Change Bowel Habit, CFB to CYCLE 2 DAY 1 | 0.00 Scores on scale | Standard Deviation 41.574 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Change Bowel Habit, CFB to CYCLE 3 DAY 1 | -7.41 Scores on scale | Standard Deviation 22.222 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Change Bowel Habit, CFB to Pre-IDS EVALUATION | -11.11 Scores on scale | Standard Deviation 40.369 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Change Bowel Habit, CFB to END OF TREATMENT | -6.67 Scores on scale | Standard Deviation 14.907 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Troubled Pass Flatulence, CFB to CYCLE 2 DAY 1 | -3.33 Scores on scale | Standard Deviation 24.595 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Troubled Pass Flatulence, CFB to CYCLE 3 DAY 1 | -3.70 Scores on scale | Standard Deviation 35.136 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Troubled Pass Flatulence, CFB to Pre-IDS EVALUATION | 0.00 Scores on scale | Standard Deviation 29.814 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Troubled Pass Flatulence, CFB to END OF TREATMENT | -20.00 Scores on scale | Standard Deviation 29.814 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Felt Full Quick after Begin Eat, CFB to CYCLE 2 DAY 1 | 0.00 Scores on scale | Standard Deviation 41.574 |
| Niraparib | Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire | Felt Full Quick after Begin Eat, CFB to CYCLE 3 DAY 1 | -14.81 Scores on scale | Standard Deviation 33.793 |
Secondary
Number of Participants With Cancer Antigen (CA)-125 Progression by Gynecological Cancer InterGroup (GCIG) CA-125 Response Criteria
Serum samples were collected to assess CA-125 progression based on the GCIG CA-125 response criteria, which is defined as follows: Criteria 1 - For participants with elevated CA-125 levels pre-treatment that reduced to the normal range during the study, progression is defined as CA-125 ≥2× Upper limit of normal (ULN) on 2 occasions at least 1 week apart.; Criteria 2 - For participants with elevated CA-125 levels pre-treatment that did not reduce to the normal range during the study, progression is defined as CA-125 ≥2× the nadir value on 2 occasions at least 1 week apart.; Criteria 3 - For participants with CA-125 levels in the normal range pre-treatment, progression is defined as CA-125 ≥2× ULN on 2 occasions at least 1 week apart.
Time frame: At week 24
Population: Intent-to-Treat population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Platinum-taxane | Number of Participants With Cancer Antigen (CA)-125 Progression by Gynecological Cancer InterGroup (GCIG) CA-125 Response Criteria | Criteria 1 | 0 Participants |
| Platinum-taxane | Number of Participants With Cancer Antigen (CA)-125 Progression by Gynecological Cancer InterGroup (GCIG) CA-125 Response Criteria | Criteria 2 | 0 Participants |
| Platinum-taxane | Number of Participants With Cancer Antigen (CA)-125 Progression by Gynecological Cancer InterGroup (GCIG) CA-125 Response Criteria | Criteria 3 | 0 Participants |
| Niraparib | Number of Participants With Cancer Antigen (CA)-125 Progression by Gynecological Cancer InterGroup (GCIG) CA-125 Response Criteria | Criteria 1 | 0 Participants |
| Niraparib | Number of Participants With Cancer Antigen (CA)-125 Progression by Gynecological Cancer InterGroup (GCIG) CA-125 Response Criteria | Criteria 2 | 0 Participants |
| Niraparib | Number of Participants With Cancer Antigen (CA)-125 Progression by Gynecological Cancer InterGroup (GCIG) CA-125 Response Criteria | Criteria 3 | 0 Participants |
Secondary
Number of Participants With Dose Modification Due to TEAEs
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is an event that emerged during treatment having been absent pretreatment or worsened relative to the pretreatment state. Number of participants with dose modifications : permanent discontinuation, dose reduction and treatment interruption/delay due to AEs is summarized.
Time frame: Up to approximately 154 weeks
Population: Safety population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Platinum-taxane | Number of Participants With Dose Modification Due to TEAEs | Treatment Interruption/delay | 11 Participants |
| Platinum-taxane | Number of Participants With Dose Modification Due to TEAEs | Permanent Discontinuation | 5 Participants |
| Platinum-taxane | Number of Participants With Dose Modification Due to TEAEs | Dose Reduction | 14 Participants |
| Niraparib | Number of Participants With Dose Modification Due to TEAEs | Treatment Interruption/delay | 11 Participants |
| Niraparib | Number of Participants With Dose Modification Due to TEAEs | Permanent Discontinuation | 4 Participants |
| Niraparib | Number of Participants With Dose Modification Due to TEAEs | Dose Reduction | 7 Participants |
Secondary
Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants of cancer clinical studies. It characterizes the frequency and severity of adverse events using a standardized scoring system. Responses include 0 (never OR none OR Not at all); 1 (Rarely OR Mild OR A little bit); 2 (Occasionally OR Moderate OR Somewhat); 3 (Frequently OR Severe OR Quite a bit) and 4 (almost constantly OR very severe OR Very much), with a higher score indicating a higher frequency and severity of adverse events.
Time frame: Baseline (Predose), Day 8 and 15 of Cycle 1; Day 1, 8 and 15 of Cycle 2 and Cycle 3; Pre-IDS Evaluation, and End of Treatment (Up to approximately 154 weeks).
Population: Intent to Treat Population is included as the Overall Number of Participants Analyzed. 'Number Analyzed' refers to participants evaluable at the specified time points. The 0 participants analyzed represents that data was not collected or available for analysis at that particular time point for the respective Arms/Groups.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 15, Severity, 1=Mild | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 8, Severity, 3=Severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 15, Severity, 2=Moderate | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 8, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 15, Severity, 3=Severe | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 1, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 15, Severity, 4=Very severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 8, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 15, Frequency, 0=Never | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 1, Severity, 2=Moderate | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 15, Frequency, 1=Rarely | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 1, Severity, 2=Moderate | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Pre-IDS Evaluation, Frequency, 0=Never | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 1, Severity, 3=Severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Pre-IDS Evaluation, Frequency, 2=Occasionally | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 1, Severity, 4=Very severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 8, Frequency, 2=Occasionally | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 1, Frequency, 0=Never | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Baseline, Frequency, 3=Frequently | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 8, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 8, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 8, Frequency, 0=Never | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 1, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 8, Frequency, 1=Rarely | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 1, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 8, Frequency, 2=Occasionally | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 1, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 8, Frequency, 3=Frequently | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 15, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 8, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 15, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 8, Frequency, 0=Never | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 15, Severity, 1=Mild | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 8, Severity, 1=Mild | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 15, Frequency, 1=Rarely | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Baseline, Severity, 0=None | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 15, Frequency, 2=Occasionally | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 8, Severity, 2=Moderate | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 15, Frequency, 3=Frequently | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 15, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 8, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Pre-IDS Evaluation, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Pre-IDS Evaluation, Severity, 1=Mild | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Pre-IDS Evaluation, Severity, 2=Moderate | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Baseline, Severity, 1=Mild | 8 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 8, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Pre-IDS Evaluation, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 1, Frequency, 2=Occasionally | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 8, Frequency, 0=Never | 6 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Pre-IDS Evaluation, Severity, 1=Mild | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Baseline, Severity, 2=Moderate | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 15, Severity, 1=Mild | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 1, Frequency, 1=Rarely | 6 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Pre-IDS Evaluation, Severity, 2=Moderate | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 15, Severity, 2=Moderate | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Pre-IDS Evaluation, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 1, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 15, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Baseline, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 1 Day 8, Severity, 0=None | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Baseline, Severity, 1=Mild | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Baseline, Severity, 2=Moderate | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 1 Day 8, Severity, 1=Mild | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Baseline, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 15, Frequency, 0=Never | 11 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Baseline, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Baseline, Severity, 1=Mild | 7 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Baseline, Severity, 2=Moderate | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 15, Frequency, 1=Rarely | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 1 Day 8, Severity, 2=Moderate | 6 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 15, Frequency, 2=Occasionally | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Baseline, Frequency, 1=Rarely | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 1, Frequency, 3=Frequently | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Baseline, Frequency, 2=Occasionally | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 15, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Baseline, Frequency, 3=Frequently | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 1, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 8, Severity, 1=Mild | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 1 Day 8, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 8, Severity, 2=Moderate | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 1, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Baseline, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Pre-IDS Evaluation, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 8, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 8, Severity, 2=Moderate | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 1, Frequency, 0=Never | 12 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 8, Severity, 3=Severe | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 3 Day 8, Frequency, 2=Occasionally | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 8, Severity, 4=Very severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 1, Frequency, 1=Rarely | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 8, Frequency, 0=Never | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 1 Day 15, Severity, 0=None | 7 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 8, Frequency, 1=Rarely | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 1, Frequency, 2=Occasionally | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 8, Frequency, 2=Occasionally | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 1 Day 15, Severity, 1=Mild | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 8, Frequency, 3=Frequently | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 1, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 15, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 1 Day 15, Severity, 2=Moderate | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 15, Severity, 1=Mild | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 1, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 15, Severity, 2=Moderate | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 3 Day 8, Frequency, 4=Almost constantly | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 15, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 8, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 1, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 15, Frequency, 0=Never | 7 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Pre-IDS Evaluation, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 15, Frequency, 1=Rarely | 6 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 15, Severity, 1=Mild | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 1, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 3 Day 15, Frequency, 0=Never | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 1, Severity, 1=Mild | 7 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 15, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 1, Severity, 2=Moderate | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 15, Frequency, 1=Rarely | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 2 Day 1, Severity, 2=Moderate | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 15, Frequency, 2=Occasionally | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 15, Severity, 1=Mild | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 15, Frequency, 3=Frequently | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 3 Day 15, Frequency, 1=Rarely | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 15, Frequency, 4=Almost constantly | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 1, Frequency, 0=Never | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 15, Severity, 2=Moderate | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 1, Severity, 3=Severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Pre-IDS Evaluation, Frequency, 0=Never | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 1, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 15, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 1, Frequency, 0=Never | 6 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 8, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 1, Frequency, 1=Rarely | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 1, Frequency, 2=Occasionally | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 3 Day 15, Frequency, 2=Occasionally | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 1, Frequency, 3=Frequently | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 15, Frequency, 0=Never | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Pre-IDS Evaluation, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 8, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 3 Day 15, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 8, Frequency, 0=Never | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 1, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 1 Day 8, Severity, 2=Moderate | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 8, Frequency, 1=Rarely | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 1, Severity, 1=Mild | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 8, Frequency, 2=Occasionally | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 1, Frequency, 0=Never | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 8, Frequency, 3=Frequently | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 1 Day 8, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 8, Severity, 1=Mild | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Baseline, Severity, 3=Severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 15, Severity, 3=Severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 8, Severity, 2=Moderate | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 8, Frequency, 1=Rarely | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 8, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Baseline, Severity, 4=Very severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 8, Severity, 1=Mild | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 8, Frequency, 1=Rarely | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 1 Day 8, Severity, 0=None | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 1 Day 15, Severity, 0=None | 10 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 8, Frequency, 2=Occasionally | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 1 Day 8, Severity, 1=Mild | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 8, Frequency, 3=Frequently | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 1, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Baseline, Frequency, 4=Almost constantly | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 15, Frequency, 1=Rarely | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 15, Frequency, 2=Occasionally | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 15, Severity, 1=Mild | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 1, Frequency, 1=Rarely | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 15, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 15, Severity, 2=Moderate | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 8, Severity, 2=Moderate | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 15, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Baseline, Severity, 1=Mild | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 15, Frequency, 0=Never | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 8, Frequency, 2=Occasionally | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Baseline, Severity, 2=Moderate | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 8, Severity, 3=Severe | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 15, Frequency, 0=Never | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 1 Day 8, Severity, 0=None | 6 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 8, Severity, 1=Mild | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Baseline, Frequency, 0=Never | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Baseline, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 8, Severity, 2=Moderate | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 1 Day 8, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 1 Day 8, Severity, 1=Mild | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 1 Day 8, Severity, 1=Mild | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 8, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 1 Day 8, Severity, 2=Moderate | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 8, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 1 Day 8, Severity, 3=Severe | 7 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 8, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 1 Day 8, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 1 Day 8, Severity, 2=Moderate | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 1 Day 15, Severity, 0=None | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 8, Frequency, 0=Never | 10 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 1 Day 15, Severity, 1=Mild | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 15, Frequency, 3=Frequently | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 8, Frequency, 1=Rarely | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 1 Day 8, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 8, Frequency, 2=Occasionally | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 8, Frequency, 3=Frequently | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 8, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Pre-IDS Evaluation, Frequency, 0=Never | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 1 Day 8, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Pre-IDS Evaluation, Frequency, 1=Rarely | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 15, Frequency, 0=Never | 12 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Pre-IDS Evaluation, Frequency, 2=Occasionally | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 1, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Pre-IDS Evaluation, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 15, Frequency, 1=Rarely | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Pre-IDS Evaluation, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 1 Day 15, Severity, 0=None | 12 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 8, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 8, Frequency, 0=Never | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 8, Severity, 1=Mild | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 1 Day 15, Severity, 1=Mild | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 8, Severity, 2=Moderate | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 8, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Baseline, Frequency, 0=Never | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 8, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Baseline, Frequency, 1=Rarely | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 1 Day 15, Severity, 2=Moderate | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 8, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Baseline, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 8, Severity, 1=Mild | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Baseline, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 1 Day 15, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 8, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Pre-IDS Evaluation, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 8, Severity, 1=Mild | 6 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 8, Frequency, 3=Frequently | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 8, Severity, 3=Severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Pre-IDS Evaluation, Severity, 1=Mild | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 15, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 1 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 15, Severity, 1=Mild | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 8, Frequency, 1=Rarely | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 15, Severity, 2=Moderate | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Baseline, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 1 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 15, Frequency, 2=Occasionally | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 2 Day 1, Severity, 0=None | 9 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 15, Frequency, 3=Frequently | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 2 Day 1, Severity, 0=None | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 8, Frequency, 0=Never | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 1, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 2 Day 1, Severity, 1=Mild | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 1, Severity, 1=Mild | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 2 Day 1, Severity, 1=Mild | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 1, Severity, 2=Moderate | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Baseline, Severity, 0=None | 7 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 2 Day 1, Severity, 2=Moderate | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 8, Severity, 2=Moderate | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 1 Day 8, Severity, 2=Moderate | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 8, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 8, Frequency, 4=Almost constantly | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 1 Day 8, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 15, Frequency, 1=Rarely | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 2 Day 8, Severity, 3=Severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 15, Frequency, 2=Occasionally | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 1 Day 8, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 8, Frequency, 3=Frequently | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 1, Severity, 1=Mild | 6 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 1, Severity, 2=Moderate | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 1 Day 15, Severity, 0=None | 6 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 1, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 2 Day 8, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 1 Day 15, Severity, 1=Mild | 7 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 1, Frequency, 1=Rarely | 6 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 15, Frequency, 1=Rarely | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 1, Frequency, 2=Occasionally | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 1, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 1 Day 15, Severity, 2=Moderate | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 8, Severity, 0=None | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 2 Day 15, Severity, 0=None | 8 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Pre-IDS Evaluation, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Pre-IDS Evaluation, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 1 Day 15, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 15, Severity, 1=Mild | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 2 Day 1, Severity, 1=Mild | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 3 Day 1, Severity, 1=Mild | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 2 Day 1, Severity, 2=Moderate | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 15, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 2 Day 1, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 3 Day 1, Severity, 2=Moderate | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Pre-IDS Evaluation, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 15, Severity, 1=Mild | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Pre-IDS Evaluation, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 2 Day 8, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 3 Day 1, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 2 Day 8, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Baseline, Severity, 3=Severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 2 Day 15, Severity, 0=None | 6 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 3 Day 1, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Baseline, Severity, 1=Mild | 6 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 2 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Baseline, Severity, 2=Moderate | 6 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 15, Severity, 2=Moderate | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Baseline, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 3 Day 1, Severity, 0=None | 8 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Baseline, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 3 Day 8, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Baseline, Frequency, 0=Never | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 3 Day 1, Severity, 1=Mild | 6 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Baseline, Frequency, 1=Rarely | 6 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 15, Severity, 2=Moderate | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Baseline, Frequency, 2=Occasionally | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 3 Day 1, Severity, 2=Moderate | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Baseline, Frequency, 3=Frequently | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 3 Day 15, Severity, 0=None | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Baseline, Frequency, 4=Almost constantly | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 3 Day 1, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 8, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 3 Day 8, Severity, 3=Severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 8, Severity, 1=Mild | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 1 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 3 Day 8, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 1 Day 15, Severity, 2=Moderate | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 3 Day 15, Severity, 1=Mild | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 1 Day 15, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 3 Day 15, Severity, 0=None | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 1 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 2 Day 1, Frequency, 0=Never | 9 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 2 Day 1, Severity, 0=None | 8 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 3 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 2 Day 1, Severity, 1=Mild | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 3 Day 15, Severity, 2=Moderate | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 2 Day 1, Severity, 2=Moderate | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Pre-IDS Evaluation, Severity, 0=None | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 2 Day 1, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Pre-IDS Evaluation, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 2 Day 1, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 2 Day 1, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 2 Day 8, Severity, 0=None | 6 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 2 Day 1, Frequency, 1=Rarely | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 2 Day 8, Severity, 1=Mild | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 2 Day 1, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 2 Day 8, Severity, 2=Moderate | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 15, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 2 Day 8, Severity, 3=Severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 2 Day 15, Severity, 0=None | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 2 Day 8, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 2 Day 1, Frequency, 2=Occasionally | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 2 Day 15, Severity, 0=None | 10 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 2 Day 15, Severity, 1=Mild | 8 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 2 Day 15, Severity, 1=Mild | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 15, Frequency, 1=Rarely | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 2 Day 15, Severity, 2=Moderate | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 2 Day 15, Severity, 2=Moderate | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 2 Day 15, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 2 Day 1, Frequency, 3=Frequently | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 2 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 2 Day 15, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 3 Day 1, Severity, 0=None | 11 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 3 Day 1, Severity, 1=Mild | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 2 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 3 Day 1, Severity, 2=Moderate | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Baseline, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 3 Day 1, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 3 Day 1, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 3 Day 1, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 2 Day 1, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 3 Day 8, Severity, 0=None | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 3 Day 1, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 3 Day 8, Severity, 1=Mild | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Baseline, Severity, 1=Mild | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 3 Day 8, Severity, 2=Moderate | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 3 Day 8, Severity, 0=None | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 3 Day 8, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 8, Severity, 1=Mild | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 3 Day 8, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 3 Day 8, Severity, 1=Mild | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 3 Day 15, Severity, 0=None | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Baseline, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 3 Day 15, Severity, 1=Mild | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 3 Day 8, Severity, 2=Moderate | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 3 Day 15, Severity, 2=Moderate | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 2 Day 8, Frequency, 0=Never | 7 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 3 Day 15, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 3 Day 15, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 3 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 8, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Pre-IDS Evaluation, Severity, 0=None | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 3 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Pre-IDS Evaluation, Severity, 1=Mild | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 15, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Pre-IDS Evaluation, Severity, 2=Moderate | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Pre-IDS Evaluation, Severity, 0=None | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Pre-IDS Evaluation, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 8, Severity, 1=Mild | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Pre-IDS Evaluation, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 2 Day 8, Frequency, 1=Rarely | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Pre-IDS Evaluation, Severity, 1=Mild | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 2 Day 8, Severity, 3=Severe | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 8, Severity, 2=Moderate | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 2 Day 8, Severity, 4=Very severe | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Baseline, Frequency, 1=Rarely | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Baseline, Frequency, 0=Never | 8 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 2 Day 15, Severity, 0=None | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Baseline, Frequency, 1=Rarely | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 2 Day 15, Severity, 1=Mild | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Baseline, Frequency, 2=Occasionally | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 3 Day 1, Severity, 0=None | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Baseline, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Pre-IDS Evaluation, Severity, 2=Moderate | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Baseline, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 1 Day 15, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 8, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Baseline, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 2 Day 15, Severity, 1=Mild | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Pre-IDS Evaluation, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 3 Day 15, Severity, 3=Severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 2 Day 8, Frequency, 2=Occasionally | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 8, Severity, 2=Moderate | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 3 Day 1, Severity, 1=Mild | 7 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 8, Severity, 3=Severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 8, Frequency, 0=Never | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 8, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 8, Frequency, 1=Rarely | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 3 Day 1, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 8, Frequency, 2=Occasionally | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 1, Frequency, 0=Never | 14 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 8, Frequency, 3=Frequently | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 3 Day 1, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 8, Frequency, 4=Almost constantly | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 8, Frequency, 0=Never | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 3 Day 8, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 15, Severity, 1=Mild | 8 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 2 Day 8, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Pre-IDS Evaluation, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 15, Severity, 3=Severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 8, Frequency, 1=Rarely | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 15, Frequency, 0=Never | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 1, Frequency, 2=Occasionally | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 15, Frequency, 1=Rarely | 6 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 8, Frequency, 2=Occasionally | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 15, Frequency, 3=Frequently | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 3 Day 15, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 1, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 2 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 1, Severity, 1=Mild | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 1, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 8, Frequency, 3=Frequently | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 1, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 8, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 8, Severity, 2=Moderate | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 8, Severity, 3=Severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 8, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 3 Day 15, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 8, Frequency, 2=Occasionally | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Baseline, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 15, Severity, 1=Mild | 7 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 2 Day 15, Frequency, 0=Never | 8 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 15, Severity, 2=Moderate | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Baseline, Severity, 1=Mild | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 15, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 15, Frequency, 2=Occasionally | 6 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 15, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 15, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Baseline, Frequency, 2=Occasionally | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 1, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 1, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Baseline, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 1, Severity, 1=Mild | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 2 Day 15, Frequency, 1=Rarely | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 1, Severity, 3=Severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Baseline, Frequency, 4=Almost constantly | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 1, Frequency, 3=Frequently | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 1, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 1, Frequency, 4=Almost constantly | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 8, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 8, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 8, Severity, 2=Moderate | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 2 Day 15, Frequency, 2=Occasionally | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 8, Severity, 3=Severe | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 8, Severity, 3=Severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Baseline, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 8, Frequency, 2=Occasionally | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 8, Severity, 4=Very severe | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 15, Frequency, 1=Rarely | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 15, Severity, 1=Mild | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 8, Frequency, 3=Frequently | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 15, Severity, 2=Moderate | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Baseline, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 8, Frequency, 4=Almost constantly | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 15, Frequency, 0=Never | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 15, Frequency, 2=Occasionally | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 15, Severity, 1=Mild | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Pre-IDS Evaluation, Frequency, 0=Never | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 2 Day 15, Frequency, 3=Frequently | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Pre-IDS Evaluation, Frequency, 1=Rarely | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Pre-IDS Evaluation, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Baseline, Frequency, 0=Never | 13 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 15, Frequency, 0=Never | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Baseline, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Baseline, Severity, 0=None | 7 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 15, Frequency, 1=Rarely | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Baseline, Severity, 1=Mild | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Baseline, Frequency, 1=Rarely | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Baseline, Severity, 2=Moderate | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 15, Frequency, 2=Occasionally | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 8, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 1 Day 15, Severity, 0=None | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 1 Day 15, Severity, 1=Mild | 6 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 15, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 2 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 1 Day 15, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 8, Severity, 1=Mild | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 1, Severity, 2=Moderate | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 1, Frequency, 1=Rarely | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 2 Day 1, Severity, 1=Mild | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 1, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 8, Severity, 2=Moderate | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 1, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 2 Day 8, Severity, 0=None | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 2 Day 8, Severity, 1=Mild | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 3 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 2 Day 8, Severity, 2=Moderate | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 8, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 2 Day 8, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 1, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 2 Day 15, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 8, Severity, 3=Severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 8, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 3 Day 1, Severity, 2=Moderate | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 8, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 3 Day 1, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 8, Severity, 1=Mild | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 3 Day 1, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 8, Severity, 2=Moderate | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 3 Day 8, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 8, Severity, 2=Moderate | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 3 Day 8, Severity, 1=Mild | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 8, Frequency, 0=Never | 10 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 3 Day 8, Severity, 2=Moderate | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 8, Severity, 3=Severe | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Baseline, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 3 Day 15, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 8, Severity, 4=Very severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 8, Frequency, 1=Rarely | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 3 Day 15, Severity, 2=Moderate | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 15, Severity, 2=Moderate | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 1, Severity, 1=Mild | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 15, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 1, Frequency, 0=Never | 6 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 1, Severity, 2=Moderate | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 15, Frequency, 0=Never | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 15, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Pre-IDS Evaluation, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Pre-IDS Evaluation, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Pre-IDS Evaluation, Frequency, 0=Never | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 8, Severity, 1=Mild | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Pre-IDS Evaluation, Frequency, 1=Rarely | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 3 Day 8, Frequency, 3=Frequently | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Pre-IDS Evaluation, Frequency, 2=Occasionally | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 8, Severity, 2=Moderate | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Pre-IDS Evaluation, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 1, Frequency, 3=Frequently | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Pre-IDS Evaluation, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 8, Severity, 3=Severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 3 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 8, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 15, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 8, Frequency, 0=Never | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Pre-IDS Evaluation, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 1 Day 15, Severity, 1=Mild | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 8, Frequency, 1=Rarely | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Baseline, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Pre-IDS Evaluation, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 8, Frequency, 2=Occasionally | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 15, Frequency, 2=Occasionally | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 8, Frequency, 3=Frequently | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 8, Frequency, 2=Occasionally | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Baseline, Frequency, 0=Never | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 15, Frequency, 1=Rarely | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Baseline, Frequency, 1=Rarely | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Pre-IDS Evaluation, Frequency, 0=Never | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Baseline, Severity, 3=Severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Baseline, Frequency, 2=Occasionally | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 15, Frequency, 2=Occasionally | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Baseline, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 8, Frequency, 3=Frequently | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Baseline, Frequency, 0=Never | 9 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 15, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Baseline, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Pre-IDS Evaluation, Frequency, 1=Rarely | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Baseline, Frequency, 4=Almost constantly | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 8, Severity, 0=None | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 15, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Pre-IDS Evaluation, Frequency, 0=Never | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 8, Severity, 3=Severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 8, Severity, 1=Mild | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Pre-IDS Evaluation, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 8, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Pre-IDS Evaluation, Frequency, 1=Rarely | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 15, Severity, 1=Mild | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Pre-IDS Evaluation, Frequency, 2=Occasionally | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 8, Frequency, 0=Never | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Pre-IDS Evaluation, Frequency, 1=Rarely | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 8, Frequency, 1=Rarely | 6 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 8, Frequency, 4=Almost constantly | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Baseline, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 15, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Baseline, Severity, 0=None | 10 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 8, Frequency, 2=Occasionally | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Pre-IDS Evaluation, Severity, 2=Moderate | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 8, Frequency, 3=Frequently | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Baseline, Severity, 0=None | 8 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Baseline, Severity, 1=Mild | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 15, Frequency, 2=Occasionally | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Baseline, Severity, 1=Mild | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 15, Frequency, 3=Frequently | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Pre-IDS Evaluation, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Baseline, Severity, 2=Moderate | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 1, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Baseline, Severity, 2=Moderate | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 15, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 15, Severity, 2=Moderate | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Baseline, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 15, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 15, Severity, 1=Mild | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 15, Severity, 4=Very severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Pre-IDS Evaluation, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 15, Frequency, 0=Never | 7 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 15, Severity, 2=Moderate | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 1, Severity, 2=Moderate | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Baseline, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 15, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 15, Frequency, 1=Rarely | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 2 Day 1, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 15, Frequency, 2=Occasionally | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 1, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 15, Frequency, 4=Almost constantly | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 2 Day 1, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 15, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 1, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 1, Severity, 1=Mild | 7 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 15, Frequency, 0=Never | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 15, Frequency, 4=Almost constantly | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 1, Frequency, 0=Never | 11 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 1, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 2 Day 8, Severity, 0=None | 6 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 1, Severity, 1=Mild | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 1, Frequency, 1=Rarely | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 1, Severity, 2=Moderate | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 1, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 1, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 1, Frequency, 2=Occasionally | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 1, Frequency, 1=Rarely | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 2 Day 8, Severity, 1=Mild | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 1, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 1, Frequency, 2=Occasionally | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 1, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 3 Day 1, Frequency, 0=Never | 8 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 1, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 1, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 1, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 2 Day 8, Severity, 2=Moderate | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 8, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 8, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 15, Frequency, 0=Never | 6 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 1, Frequency, 0=Never | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 8, Severity, 1=Mild | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 15, Frequency, 2=Occasionally | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 2 Day 15, Severity, 1=Mild | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 1, Frequency, 1=Rarely | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 1, Frequency, 2=Occasionally | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 3 Day 1, Frequency, 1=Rarely | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 1, Frequency, 3=Frequently | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 2 Day 15, Severity, 2=Moderate | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 1, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Baseline, Severity, 3=Severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 8, Severity, 2=Moderate | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 8, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 2 Day 15, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 3 Day 1, Frequency, 2=Occasionally | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 8, Severity, 1=Mild | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 1, Frequency, 1=Rarely | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 8, Severity, 3=Severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 2 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 8, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 8, Frequency, 0=Never | 9 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 8, Severity, 2=Moderate | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 1, Frequency, 0=Never | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 8, Severity, 3=Severe | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 8, Frequency, 1=Rarely | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 8, Severity, 4=Very severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 3 Day 1, Severity, 0=None | 12 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 8, Frequency, 0=Never | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 8, Frequency, 0=Never | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 8, Frequency, 2=Occasionally | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 8, Frequency, 1=Rarely | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 3 Day 1, Frequency, 3=Frequently | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 8, Frequency, 1=Rarely | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 8, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 8, Frequency, 2=Occasionally | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 15, Frequency, 2=Occasionally | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 8, Frequency, 2=Occasionally | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 3 Day 8, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 8, Frequency, 3=Frequently | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 3 Day 1, Frequency, 4=Almost constantly | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 8, Frequency, 4=Almost constantly | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 8, Frequency, 3=Frequently | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 3 Day 8, Severity, 1=Mild | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 1, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 15, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 15, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 15, Severity, 0=None | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 3 Day 8, Severity, 2=Moderate | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 15, Severity, 1=Mild | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Pre-IDS Evaluation, Frequency, 2=Occasionally | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 15, Severity, 2=Moderate | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 3 Day 8, Frequency, 0=Never | 7 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 15, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 1 Day 15, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 15, Severity, 4=Very severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 3 Day 8, Severity, 3=Severe | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 15, Severity, 1=Mild | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 15, Frequency, 0=Never | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 1 Day 8, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 3 Day 15, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 15, Severity, 2=Moderate | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 3 Day 8, Frequency, 1=Rarely | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 15, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Baseline, Severity, 1=Mild | 6 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 3 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 15, Frequency, 0=Never | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Baseline, Severity, 2=Moderate | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 15, Frequency, 1=Rarely | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 15, Frequency, 2=Occasionally | 6 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Baseline, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Pre-IDS Evaluation, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Baseline, Severity, 4=Very severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Baseline, Severity, 2=Moderate | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 1, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 1 Day 8, Severity, 0=None | 7 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Pre-IDS Evaluation, Severity, 1=Mild | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 1, Severity, 1=Mild | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 1, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 1 Day 8, Severity, 1=Mild | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 1 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 1, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 1, Severity, 2=Moderate | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Baseline, Frequency, 2=Occasionally | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 2 Day 1, Severity, 0=None | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 1, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Pre-IDS Evaluation, Severity, 2=Moderate | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 2 Day 1, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 1, Frequency, 1=Rarely | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 8, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 1, Severity, 2=Moderate | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 2 Day 8, Severity, 0=None | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 8, Severity, 1=Mild | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 1, Frequency, 2=Occasionally | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Pre-IDS Evaluation, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 8, Severity, 2=Moderate | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 2 Day 8, Severity, 1=Mild | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 1 Day 8, Severity, 3=Severe | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 8, Severity, 3=Severe | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 1, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 2 Day 8, Severity, 2=Moderate | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 8, Frequency, 4=Almost constantly | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 1, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 15, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 2 Day 15, Severity, 1=Mild | 7 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 15, Severity, 1=Mild | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Baseline, Severity, 2=Moderate | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 8, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 15, Severity, 2=Moderate | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 2 Day 15, Severity, 2=Moderate | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 15, Frequency, 0=Never | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 15, Frequency, 1=Rarely | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 2 Day 15, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 15, Frequency, 2=Occasionally | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 3 Day 1, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 8, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Baseline, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 15, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 8, Frequency, 0=Never | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 3 Day 8, Severity, 0=None | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 15, Frequency, 0=Never | 6 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 15, Frequency, 4=Almost constantly | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Pre-IDS Evaluation, Frequency, 1=Rarely | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 3 Day 8, Severity, 1=Mild | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Pre-IDS Evaluation, Frequency, 2=Occasionally | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Baseline, Frequency, 0=Never | 7 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 3 Day 8, Severity, 2=Moderate | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 15, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Pre-IDS Evaluation, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 1, Frequency, 2=Occasionally | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 3 Day 15, Severity, 1=Mild | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Pre-IDS Evaluation, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Baseline, Frequency, 1=Rarely | 6 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Baseline, Severity, 0=None | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 3 Day 15, Severity, 2=Moderate | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Baseline, Severity, 1=Mild | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Baseline, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Baseline, Severity, 2=Moderate | 8 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 3 Day 15, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Baseline, Severity, 3=Severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Baseline, Frequency, 2=Occasionally | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 2 Day 8, Severity, 0=None | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 1 Day 15, Severity, 2=Moderate | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 15, Frequency, 2=Occasionally | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 1 Day 15, Severity, 3=Severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 2 Day 8, Severity, 1=Mild | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 1 Day 15, Severity, 4=Very severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Baseline, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 2 Day 1, Severity, 0=None | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 2 Day 8, Severity, 2=Moderate | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 2 Day 1, Severity, 1=Mild | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 2 Day 1, Severity, 2=Moderate | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 15, Severity, 1=Mild | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 2 Day 1, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 2 Day 8, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 2 Day 1, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Baseline, Severity, 1=Mild | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 2 Day 8, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 2 Day 8, Severity, 4=Very severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 15, Severity, 2=Moderate | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 15, Frequency, 1=Rarely | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 3 Day 1, Severity, 0=None | 8 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 2 Day 8, Severity, 1=Mild | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 15, Frequency, 3=Frequently | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 15, Frequency, 2=Occasionally | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 3 Day 1, Severity, 1=Mild | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 15, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 15, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 2 Day 8, Severity, 2=Moderate | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 3 Day 1, Severity, 2=Moderate | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Baseline, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 3 Day 8, Severity, 3=Severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Baseline, Severity, 1=Mild | 8 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Baseline, Severity, 2=Moderate | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 3 Day 8, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Baseline, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 15, Frequency, 0=Never | 8 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Baseline, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 3 Day 15, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 8, Severity, 2=Moderate | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 1, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 8, Severity, 3=Severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 3 Day 15, Severity, 1=Mild | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 8, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 15, Frequency, 1=Rarely | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 8, Frequency, 0=Never | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 3 Day 15, Severity, 2=Moderate | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 8, Frequency, 1=Rarely | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Pre-IDS Evaluation, Severity, 1=Mild | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 8, Frequency, 2=Occasionally | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 1, Severity, 1=Mild | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Pre-IDS Evaluation, Severity, 2=Moderate | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 15, Frequency, 2=Occasionally | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Pre-IDS Evaluation, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 15, Frequency, 0=Never | 6 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 15, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 15, Frequency, 1=Rarely | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 1, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Pre-IDS Evaluation, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 1, Frequency, 0=Never | 6 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 1, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 1, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Baseline, Frequency, 2=Occasionally | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 1, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 3 Day 1, Severity, 2=Moderate | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 8, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 8, Severity, 4=Very severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 2 Day 15, Severity, 2=Moderate | 7 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 8, Frequency, 0=Never | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 8, Frequency, 1=Rarely | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Baseline, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 8, Frequency, 2=Occasionally | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 2 Day 15, Severity, 3=Severe | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 8, Frequency, 3=Frequently | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 15, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 8, Frequency, 4=Almost constantly | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 2 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Baseline, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 15, Severity, 2=Moderate | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Baseline, Frequency, 2=Occasionally | 8 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 8, Severity, 2=Moderate | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 3 Day 8, Severity, 1=Mild | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 8, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 8, Frequency, 2=Occasionally | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 3 Day 8, Severity, 2=Moderate | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 8, Frequency, 1=Rarely | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 1, Frequency, 0=Never | 7 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 3 Day 8, Severity, 3=Severe | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 15, Severity, 2=Moderate | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 8, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 15, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 3 Day 8, Severity, 4=Very severe | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 15, Frequency, 0=Never | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 15, Frequency, 2=Occasionally | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 15, Frequency, 1=Rarely | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 3 Day 15, Severity, 1=Mild | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 15, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 3 Day 15, Severity, 2=Moderate | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 8, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Pre-IDS Evaluation, Frequency, 0=Never | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Baseline, Severity, 2=Moderate | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Pre-IDS Evaluation, Frequency, 2=Occasionally | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 1, Frequency, 2=Occasionally | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Baseline, Severity, 3=Severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 8, Severity, 1=Mild | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 1 Day 8, Frequency, 0=Never | 8 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Baseline, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 1 Day 8, Frequency, 1=Rarely | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 15, Frequency, 3=Frequently | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 1 Day 8, Frequency, 2=Occasionally | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Baseline, Frequency, 0=Never | 11 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 1 Day 8, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 8, Frequency, 0=Never | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 1 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Baseline, Frequency, 1=Rarely | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 1 Day 15, Frequency, 0=Never | 11 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 15, Frequency, 0=Never | 14 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 1 Day 15, Frequency, 1=Rarely | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 8, Severity, 1=Mild | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 1 Day 15, Frequency, 2=Occasionally | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 8, Severity, 1=Mild | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 3 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 8, Frequency, 0=Never | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Pre-IDS Evaluation, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 15, Frequency, 1=Rarely | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 8, Frequency, 1=Rarely | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 8, Severity, 4=Very severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 8, Frequency, 1=Rarely | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 15, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 15, Severity, 2=Moderate | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 8, Frequency, 2=Occasionally | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 15, Frequency, 2=Occasionally | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 15, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 15, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 1, Severity, 2=Moderate | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Pre-IDS Evaluation, Frequency, 1=Rarely | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 15, Severity, 2=Moderate | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 1, Frequency, 0=Never | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 15, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 1, Frequency, 1=Rarely | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 15, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 1, Frequency, 2=Occasionally | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 1, Severity, 1=Mild | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 1, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 15, Severity, 4=Very severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 1, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 15, Frequency, 4=Almost constantly | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 8, Severity, 1=Mild | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 8, Frequency, 4=Almost constantly | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 8, Severity, 2=Moderate | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 1, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 8, Frequency, 0=Never | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 1, Severity, 2=Moderate | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 8, Frequency, 1=Rarely | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 1, Severity, 1=Mild | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 1, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 8, Frequency, 3=Frequently | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 15, Severity, 1=Mild | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 8, Frequency, 4=Almost constantly | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 1, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 15, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 1, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 1, Frequency, 0=Never | 8 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 15, Frequency, 0=Never | 6 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 15, Severity, 1=Mild | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 15, Frequency, 1=Rarely | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 1, Frequency, 1=Rarely | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 1, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 1, Severity, 2=Moderate | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 1, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 1, Frequency, 2=Occasionally | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 1, Frequency, 0=Never | 6 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 15, Severity, 2=Moderate | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 1, Frequency, 1=Rarely | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 8, Frequency, 0=Never | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 1, Frequency, 2=Occasionally | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 1, Frequency, 0=Never | 9 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 8, Severity, 1=Mild | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 8, Frequency, 1=Rarely | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 8, Severity, 2=Moderate | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 8, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 15, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 8, Frequency, 0=Never | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 8, Frequency, 2=Occasionally | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 8, Frequency, 1=Rarely | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 8, Frequency, 3=Frequently | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 1, Frequency, 1=Rarely | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 8, Frequency, 3=Frequently | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 15, Severity, 0=None | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 15, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 15, Frequency, 0=Never | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 8, Frequency, 4=Almost constantly | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 15, Frequency, 1=Rarely | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 1, Frequency, 2=Occasionally | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 15, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 15, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 8, Frequency, 1=Rarely | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 1, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Pre-IDS Evaluation, Frequency, 2=Occasionally | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 15, Frequency, 2=Occasionally | 4 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Pre-IDS Evaluation, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 8, Frequency, 2=Occasionally | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 15, Frequency, 3=Frequently | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 8, Frequency, 2=Occasionally | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 15, Frequency, 4=Almost constantly | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 8, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 1, Severity, 0=None | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 15, Frequency, 2=Occasionally | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 1, Severity, 1=Mild | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Baseline, Severity, 3=Severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 1, Frequency, 1=Rarely | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Baseline, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 15, Frequency, 3=Frequently | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 1 Day 8, Severity, 0=None | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 1, Frequency, 2=Occasionally | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 1 Day 8, Severity, 1=Mild | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 15, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 1 Day 8, Severity, 2=Moderate | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 1, Frequency, 3=Frequently | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 1 Day 8, Severity, 3=Severe | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 1 Day 8, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 1, Frequency, 4=Almost constantly | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 1 Day 15, Severity, 2=Moderate | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 1 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 2 Day 1, Severity, 0=None | 6 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 2 Day 1, Severity, 2=Moderate | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 2 Day 1, Severity, 3=Severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 2 Day 1, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Pre-IDS Evaluation, Frequency, 0=Never | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 8, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 2 Day 8, Severity, 3=Severe | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 8, Severity, 1=Mild | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Pre-IDS Evaluation, Frequency, 1=Rarely | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 2 Day 15, Severity, 2=Moderate | 5 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 8, Severity, 2=Moderate | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 2 Day 15, Severity, 3=Severe | 2 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 1, Severity, 0=None | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 2 Day 15, Severity, 4=Very severe | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 3 Day 1, Severity, 0=None | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 8, Severity, 3=Severe | 3 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 3 Day 1, Severity, 1=Mild | 8 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Pre-IDS Evaluation, Frequency, 2=Occasionally | 0 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 3 Day 8, Severity, 3=Severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 3 Day 8, Severity, 4=Very severe | 1 Participants |
| Platinum-taxane | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 3 Day 15, Severity, 1=Mild | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 8, Frequency, 0=Never | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 8, Frequency, 1=Rarely | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 8, Frequency, 2=Occasionally | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 8, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 15, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 15, Frequency, 0=Never | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 15, Frequency, 1=Rarely | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 1, Severity, 1=Mild | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 1, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 1, Frequency, 0=Never | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 1, Frequency, 1=Rarely | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 1, Frequency, 2=Occasionally | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 8, Severity, 1=Mild | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 8, Frequency, 0=Never | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 8, Frequency, 3=Frequently | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 15, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 15, Frequency, 0=Never | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 15, Frequency, 1=Rarely | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 15, Frequency, 2=Occasionally | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 15, Frequency, 3=Frequently | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Pre-IDS Evaluation, Frequency, 1=Rarely | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Pre-IDS Evaluation, Frequency, 2=Occasionally | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Pre-IDS Evaluation, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, End Of Treatment, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, End Of Treatment, Severity, 1=Mild | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, End Of Treatment, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, End Of Treatment, Frequency, 0=Never | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, End Of Treatment, Frequency, 1=Rarely | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, End Of Treatment, Frequency, 2=Occasionally | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, End Of Treatment, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, End Of Treatment, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Baseline, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Baseline, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 1 Day 8, Severity, 0=None | 11 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 1 Day 8, Severity, 1=Mild | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 1 Day 8, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 1 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 1 Day 15, Severity, 0=None | 11 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 2 Day 1, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 2 Day 8, Severity, 0=None | 10 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 2 Day 8, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 2 Day 15, Severity, 0=None | 13 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 2 Day 15, Severity, 1=Mild | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 2 Day 15, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 2 Day 15, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 3 Day 1, Severity, 0=None | 13 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 3 Day 8, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 1, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 15, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 15, Severity, 4=Very severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 15, Frequency, 2=Occasionally | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 15, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 1, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 1, Frequency, 1=Rarely | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 1, Frequency, 2=Occasionally | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 8, Frequency, 1=Rarely | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 15, Severity, 0=None | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 15, Severity, 3=Severe | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 1, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 1, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Baseline, Severity, 2=Moderate | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 15, Frequency, 2=Occasionally | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 1, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 1, Frequency, 3=Frequently | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 15, Frequency, 1=Rarely | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, End Of Treatment, Severity, 1=Mild | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, End Of Treatment, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Baseline, Severity, 0=None | 7 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Baseline, Severity, 1=Mild | 7 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Baseline, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 1 Day 8, Severity, 0=None | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 1 Day 8, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 1 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 1 Day 15, Severity, 0=None | 7 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 1 Day 15, Severity, 1=Mild | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 1 Day 15, Severity, 2=Moderate | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 2 Day 1, Severity, 1=Mild | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 3 Day 1, Severity, 1=Mild | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 1, Frequency, 2=Occasionally | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 1, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 1, Frequency, 2=Occasionally | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 1, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 8, Frequency, 1=Rarely | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 8, Frequency, 2=Occasionally | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 8, Frequency, 3=Frequently | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 15, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Pre-IDS Evaluation, Frequency, 1=Rarely | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Pre-IDS Evaluation, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, End Of Treatment, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 1 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 2 Day 1, Frequency, 0=Never | 12 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 2 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 3 Day 1, Frequency, 0=Never | 12 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 3 Day 1, Frequency, 1=Rarely | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 3 Day 1, Frequency, 2=Occasionally | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 3 Day 1, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 3 Day 1, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 3 Day 8, Frequency, 0=Never | 8 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, End Of Treatment, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 1, Severity, 2=Moderate | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 15, Frequency, 0=Never | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 15, Frequency, 1=Rarely | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 15, Frequency, 2=Occasionally | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 15, Frequency, 3=Frequently | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 1, Severity, 1=Mild | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 1, Frequency, 0=Never | 8 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 1, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 1, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 1, Frequency, 0=Never | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 8, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 8, Severity, 1=Mild | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 8, Frequency, 0=Never | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 8, Frequency, 1=Rarely | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 8, Frequency, 3=Frequently | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 15, Severity, 1=Mild | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 15, Frequency, 0=Never | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 1, Frequency, 1=Rarely | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 1, Frequency, 3=Frequently | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 3 Day 8, Frequency, 1=Rarely | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 3 Day 15, Frequency, 2=Occasionally | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 1 Day 15, Severity, 0=None | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Pre-IDS Evaluation, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, End Of Treatment, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, End Of Treatment, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, End Of Treatment, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, End Of Treatment, Frequency, 0=Never | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, End Of Treatment, Frequency, 1=Rarely | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, End Of Treatment, Frequency, 2=Occasionally | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, End Of Treatment, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, End Of Treatment, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Baseline, Severity, 0=None | 9 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Baseline, Severity, 1=Mild | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Baseline, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 2 Day 1, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 2 Day 1, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 2 Day 8, Severity, 0=None | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 2 Day 8, Severity, 1=Mild | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 2 Day 8, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 2 Day 15, Severity, 1=Mild | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 2 Day 15, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 2 Day 15, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 2 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 3 Day 1, Severity, 0=None | 8 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 3 Day 1, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 3 Day 8, Severity, 0=None | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 3 Day 8, Severity, 1=Mild | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 3 Day 8, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 3 Day 15, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 3 Day 15, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 3 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Pre-IDS Evaluation, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Pre-IDS Evaluation, Severity, 1=Mild | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Pre-IDS Evaluation, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Pre-IDS Evaluation, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Baseline, Severity, 1=Mild | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Baseline, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Baseline, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Baseline, Severity, 4=Very severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Baseline, Frequency, 0=Never | 8 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Baseline, Frequency, 1=Rarely | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Baseline, Frequency, 2=Occasionally | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 15, Severity, 1=Mild | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 15, Severity, 2=Moderate | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 15, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 15, Frequency, 0=Never | 7 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 15, Frequency, 1=Rarely | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 15, Frequency, 3=Frequently | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Baseline, Frequency, 1=Rarely | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Baseline, Frequency, 2=Occasionally | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Baseline, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Baseline, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 8, Frequency, 2=Occasionally | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 8, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 15, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 15, Severity, 1=Mild | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 15, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 15, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 15, Frequency, 0=Never | 12 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 15, Frequency, 1=Rarely | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Pre-IDS Evaluation, Frequency, 0=Never | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Pre-IDS Evaluation, Frequency, 1=Rarely | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 1, Severity, 1=Mild | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 1, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 1, Severity, 3=Severe | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 1, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 1, Frequency, 0=Never | 7 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 1, Frequency, 1=Rarely | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 8, Frequency, 1=Rarely | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 8, Frequency, 2=Occasionally | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 8, Frequency, 3=Frequently | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 15, Severity, 0=None | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 15, Frequency, 3=Frequently | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 1, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 1, Severity, 1=Mild | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 1, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 8, Severity, 1=Mild | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 8, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 8, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 8, Frequency, 0=Never | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 8, Frequency, 1=Rarely | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 8, Frequency, 2=Occasionally | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 15, Frequency, 0=Never | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 15, Frequency, 1=Rarely | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 15, Frequency, 2=Occasionally | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 15, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Pre-IDS Evaluation, Frequency, 0=Never | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Pre-IDS Evaluation, Frequency, 1=Rarely | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Pre-IDS Evaluation, Frequency, 2=Occasionally | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, End Of Treatment, Frequency, 2=Occasionally | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, End Of Treatment, Frequency, 3=Frequently | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, End Of Treatment, Frequency, 4=Almost constantly | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Baseline, Severity, 0=None | 9 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Baseline, Severity, 1=Mild | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Baseline, Severity, 2=Moderate | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 15, Severity, 0=None | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 15, Severity, 1=Mild | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 15, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 15, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 15, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 15, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 1, Frequency, 0=Never | 12 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 1, Frequency, 1=Rarely | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 1, Frequency, 2=Occasionally | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 1, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 1, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 8, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 15, Frequency, 2=Occasionally | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 1, Severity, 1=Mild | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 1, Severity, 3=Severe | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 1, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 1, Frequency, 0=Never | 11 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 1, Frequency, 1=Rarely | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 8, Frequency, 0=Never | 9 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 8, Frequency, 1=Rarely | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 8, Frequency, 2=Occasionally | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 8, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 15, Severity, 0=None | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 15, Severity, 1=Mild | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 15, Frequency, 2=Occasionally | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Pre-IDS Evaluation, Frequency, 1=Rarely | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 2 Day 1, Severity, 1=Mild | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, End Of Treatment, Severity, 0=None | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, End Of Treatment, Severity, 1=Mild | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, End Of Treatment, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, End Of Treatment, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Baseline, Severity, 1=Mild | 8 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Baseline, Severity, 2=Moderate | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Baseline, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Baseline, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 1 Day 8, Severity, 0=None | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 1 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 2 Day 1, Severity, 0=None | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 2 Day 1, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 2 Day 8, Severity, 0=None | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 2 Day 8, Severity, 1=Mild | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 2 Day 15, Severity, 0=None | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 2 Day 15, Severity, 1=Mild | 7 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 2 Day 15, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 3 Day 1, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 3 Day 1, Severity, 4=Very severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 3 Day 8, Severity, 0=None | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 3 Day 8, Severity, 1=Mild | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 3 Day 8, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 3 Day 15, Severity, 1=Mild | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 3 Day 15, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 3 Day 15, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 2 Day 8, Severity, 0=None | 7 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 2 Day 8, Severity, 1=Mild | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 2 Day 8, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 2 Day 8, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 2 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 3 Day 1, Severity, 0=None | 9 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 3 Day 1, Severity, 1=Mild | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 3 Day 1, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 3 Day 8, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 3 Day 8, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 3 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 3 Day 15, Severity, 0=None | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 3 Day 15, Severity, 1=Mild | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Pre-IDS Evaluation, Severity, 1=Mild | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Pre-IDS Evaluation, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Pre-IDS Evaluation, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Pre-IDS Evaluation, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Pre-IDS Evaluation, Severity, 1=Mild | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 2 Day 15, Severity, 1=Mild | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 2 Day 15, Severity, 2=Moderate | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 2 Day 15, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 2 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 3 Day 8, Severity, 0=None | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 3 Day 8, Severity, 1=Mild | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 3 Day 8, Severity, 2=Moderate | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 3 Day 8, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, End Of Treatment, Severity, 1=Mild | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 3 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 3 Day 15, Severity, 1=Mild | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Baseline, Severity, 1=Mild | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Baseline, Severity, 2=Moderate | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Baseline, Severity, 3=Severe | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Baseline, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Baseline, Frequency, 0=Never | 7 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 8, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 8, Severity, 1=Mild | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 8, Frequency, 0=Never | 8 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 8, Frequency, 1=Rarely | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 8, Frequency, 2=Occasionally | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 15, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 15, Severity, 2=Moderate | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 15, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 1, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 1, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 1, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 1, Frequency, 0=Never | 8 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 1, Frequency, 1=Rarely | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 1, Frequency, 2=Occasionally | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 8, Frequency, 0=Never | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 8, Frequency, 1=Rarely | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 8, Frequency, 2=Occasionally | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 8, Frequency, 3=Frequently | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 15, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 15, Frequency, 1=Rarely | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 15, Frequency, 2=Occasionally | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 15, Frequency, 3=Frequently | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 1, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 1, Severity, 1=Mild | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 1, Frequency, 1=Rarely | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 1, Frequency, 2=Occasionally | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 1, Frequency, 3=Frequently | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 1, Frequency, 4=Almost constantly | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 8, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 8, Severity, 1=Mild | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 8, Severity, 2=Moderate | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 8, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 15, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 15, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 15, Frequency, 0=Never | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Pre-IDS Evaluation, Frequency, 0=Never | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Pre-IDS Evaluation, Frequency, 1=Rarely | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Pre-IDS Evaluation, Frequency, 2=Occasionally | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Pre-IDS Evaluation, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Pre-IDS Evaluation, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, End Of Treatment, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, End Of Treatment, Severity, 1=Mild | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, End Of Treatment, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, End Of Treatment, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Pre-IDS Evaluation, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, End Of Treatment, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, End Of Treatment, Severity, 0=None | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Baseline, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, End Of Treatment, Severity, 1=Mild | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, End Of Treatment, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, End Of Treatment, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Baseline, Frequency, 0=Never | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Baseline, Frequency, 1=Rarely | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Baseline, Severity, 3=Severe | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Baseline, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Baseline, Frequency, 2=Occasionally | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Baseline, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Baseline, Frequency, 4=Almost constantly | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 8, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 8, Severity, 2=Moderate | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 8, Severity, 3=Severe | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 8, Severity, 1=Mild | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 8, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 8, Frequency, 0=Never | 7 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 8, Frequency, 4=Almost constantly | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 8, Frequency, 1=Rarely | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 8, Frequency, 2=Occasionally | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 8, Frequency, 3=Frequently | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 15, Frequency, 1=Rarely | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 15, Frequency, 2=Occasionally | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 15, Frequency, 3=Frequently | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 1, Severity, 0=None | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 15, Severity, 1=Mild | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 15, Severity, 2=Moderate | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 15, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 1, Severity, 1=Mild | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 1, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 15, Frequency, 0=Never | 8 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 15, Frequency, 1=Rarely | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 1, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 15, Frequency, 2=Occasionally | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 1, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 15, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 1, Severity, 0=None | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 1, Severity, 1=Mild | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 1, Severity, 2=Moderate | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 1, Frequency, 0=Never | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 1, Frequency, 1=Rarely | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 8, Frequency, 4=Almost constantly | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 1, Frequency, 2=Occasionally | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 1, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 1, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 1, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 8, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 8, Severity, 1=Mild | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 1, Frequency, 0=Never | 8 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 1, Frequency, 1=Rarely | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 1, Frequency, 2=Occasionally | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 1, Frequency, 3=Frequently | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 1, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 8, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 8, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 8, Severity, 1=Mild | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 8, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 8, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 8, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 8, Frequency, 0=Never | 7 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 8, Frequency, 0=Never | 7 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 8, Frequency, 1=Rarely | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 8, Frequency, 1=Rarely | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 8, Frequency, 2=Occasionally | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 8, Frequency, 2=Occasionally | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 8, Frequency, 3=Frequently | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 8, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 15, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 15, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 15, Severity, 1=Mild | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 15, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 15, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 15, Severity, 1=Mild | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 15, Frequency, 0=Never | 9 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 15, Severity, 2=Moderate | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 15, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 15, Frequency, 0=Never | 8 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 15, Frequency, 1=Rarely | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 15, Frequency, 2=Occasionally | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 15, Frequency, 3=Frequently | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 2 Day 15, Frequency, 4=Almost constantly | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 1, Severity, 0=None | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 1, Severity, 2=Moderate | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 1, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 1, Severity, 1=Mild | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 1, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 1, Frequency, 3=Frequently | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 1, Frequency, 4=Almost constantly | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 1, Frequency, 0=Never | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 1, Frequency, 1=Rarely | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 8, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 8, Severity, 1=Mild | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 1, Frequency, 2=Occasionally | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 8, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 8, Frequency, 3=Frequently | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 15, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 15, Severity, 1=Mild | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 8, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 15, Frequency, 0=Never | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 15, Frequency, 1=Rarely | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 15, Frequency, 2=Occasionally | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 8, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 15, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 8, Frequency, 0=Never | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Pre-IDS Evaluation, Frequency, 1=Rarely | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Pre-IDS Evaluation, Frequency, 2=Occasionally | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 15, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Pre-IDS Evaluation, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, End Of Treatment, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Baseline, Severity, 0=None | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Baseline, Severity, 1=Mild | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Baseline, Severity, 2=Moderate | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Baseline, Severity, 3=Severe | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 1 Day 15, Severity, 1=Mild | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 1 Day 15, Severity, 2=Moderate | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 1 Day 15, Severity, 3=Severe | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 1 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 2 Day 1, Severity, 0=None | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 2 Day 1, Severity, 2=Moderate | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 2 Day 1, Severity, 3=Severe | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 2 Day 1, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 2 Day 8, Severity, 0=None | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 15, Frequency, 0=Never | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 15, Frequency, 1=Rarely | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 2 Day 8, Severity, 1=Mild | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 15, Frequency, 2=Occasionally | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 15, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, End Of Treatment, Frequency, 1=Rarely | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, End Of Treatment, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, End Of Treatment, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Baseline, Severity, 0=None | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Baseline, Severity, 1=Mild | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Baseline, Severity, 2=Moderate | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Baseline, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 8, Severity, 1=Mild | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 8, Severity, 2=Moderate | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 8, Severity, 3=Severe | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 8, Frequency, 0=Never | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 8, Frequency, 1=Rarely | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 8, Frequency, 2=Occasionally | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 15, Severity, 3=Severe | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 2 Day 8, Severity, 2=Moderate | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 15, Frequency, 0=Never | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 1, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 1, Frequency, 0=Never | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 1, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 1, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 8, Frequency, 1=Rarely | 8 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 8, Frequency, 2=Occasionally | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 8, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 15, Severity, 0=None | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 15, Severity, 1=Mild | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 15, Severity, 2=Moderate | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 8, Severity, 2=Moderate | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 8, Frequency, 0=Never | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 15, Severity, 1=Mild | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 15, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 15, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 15, Frequency, 2=Occasionally | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Pre-IDS Evaluation, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Pre-IDS Evaluation, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Pre-IDS Evaluation, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Pre-IDS Evaluation, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Pre-IDS Evaluation, Frequency, 0=Never | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Pre-IDS Evaluation, Frequency, 2=Occasionally | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, End Of Treatment, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Baseline, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 1 Day 8, Frequency, 0=Never | 11 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 1 Day 8, Frequency, 1=Rarely | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 1 Day 8, Frequency, 2=Occasionally | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 1 Day 8, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 1 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 1 Day 15, Frequency, 0=Never | 10 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 1 Day 15, Frequency, 1=Rarely | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 1 Day 15, Frequency, 2=Occasionally | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 3 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Pre-IDS Evaluation, Severity, 0=None | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 8, Severity, 3=Severe | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 15, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 15, Frequency, 1=Rarely | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 15, Frequency, 4=Almost constantly | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 1, Severity, 1=Mild | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 1, Severity, 2=Moderate | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 1, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 1, Frequency, 0=Never | 9 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 1, Frequency, 1=Rarely | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 1, Frequency, 2=Occasionally | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 1, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 1, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 8, Severity, 1=Mild | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 8, Severity, 2=Moderate | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 3 Day 15, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 3 Day 15, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 3 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Pre-IDS Evaluation, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Pre-IDS Evaluation, Severity, 1=Mild | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Pre-IDS Evaluation, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Pre-IDS Evaluation, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Pre-IDS Evaluation, Severity, 4=Very severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, End Of Treatment, Severity, 0=None | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, End Of Treatment, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, End Of Treatment, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, End Of Treatment, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, End Of Treatment, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Baseline, Frequency, 0=Never | 10 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Baseline, Frequency, 1=Rarely | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Baseline, Frequency, 2=Occasionally | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Baseline, Frequency, 3=Frequently | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, End Of Treatment, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 3 Day 15, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 8, Severity, 1=Mild | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 8, Severity, 2=Moderate | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 8, Frequency, 0=Never | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 8, Frequency, 1=Rarely | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 8, Frequency, 2=Occasionally | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 8, Frequency, 3=Frequently | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 8, Frequency, 4=Almost constantly | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 15, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 15, Severity, 1=Mild | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 15, Severity, 2=Moderate | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 15, Frequency, 0=Never | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 15, Frequency, 2=Occasionally | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 15, Frequency, 3=Frequently | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 1, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 1, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 8, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 8, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 15, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 15, Severity, 1=Mild | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 15, Severity, 2=Moderate | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 15, Frequency, 2=Occasionally | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 15, Frequency, 3=Frequently | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 2 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 1, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 1, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 1, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 1, Frequency, 3=Frequently | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 1, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 8, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 8, Severity, 2=Moderate | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 8, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 8, Frequency, 1=Rarely | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 8, Frequency, 2=Occasionally | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 15, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 15, Severity, 1=Mild | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 15, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 3 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Pre-IDS Evaluation, Frequency, 0=Never | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Pre-IDS Evaluation, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, End Of Treatment, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, End Of Treatment, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Baseline, Severity, 0=None | 15 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Baseline, Severity, 1=Mild | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Baseline, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 1 Day 8, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 1 Day 15, Severity, 1=Mild | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 1 Day 15, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 1 Day 15, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 1 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 2 Day 1, Severity, 0=None | 14 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 2 Day 1, Severity, 1=Mild | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 2 Day 1, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 2 Day 1, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 2 Day 8, Severity, 1=Mild | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 2 Day 8, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 2 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 2 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 3 Day 1, Severity, 1=Mild | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 3 Day 1, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 3 Day 1, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 3 Day 1, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 3 Day 8, Severity, 0=None | 8 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 3 Day 8, Severity, 1=Mild | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 3 Day 8, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 3 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 3 Day 15, Severity, 0=None | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 3 Day 15, Severity, 1=Mild | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, End Of Treatment, Severity, 1=Mild | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, End Of Treatment, Severity, 1=Mild | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, End Of Treatment, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, End Of Treatment, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, End Of Treatment, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, End Of Treatment, Frequency, 0=Never | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, End Of Treatment, Frequency, 1=Rarely | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, End Of Treatment, Frequency, 2=Occasionally | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, End Of Treatment, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Baseline, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Baseline, Severity, 1=Mild | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Baseline, Severity, 2=Moderate | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Baseline, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Baseline, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Baseline, Frequency, 0=Never | 9 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Baseline, Frequency, 1=Rarely | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Baseline, Frequency, 2=Occasionally | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Baseline, Frequency, 3=Frequently | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Baseline, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 8, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 8, Severity, 1=Mild | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 8, Severity, 2=Moderate | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 8, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 8, Frequency, 0=Never | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 8, Frequency, 1=Rarely | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 8, Frequency, 2=Occasionally | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 8, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 15, Severity, 1=Mild | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 15, Severity, 2=Moderate | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 15, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 15, Frequency, 0=Never | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 15, Frequency, 1=Rarely | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 1 Day 15, Frequency, 4=Almost constantly | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 1, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 1, Severity, 1=Mild | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 1, Severity, 2=Moderate | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 1, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 1, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 8, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 8, Severity, 1=Mild | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 8, Severity, 2=Moderate | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 8, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 8, Frequency, 0=Never | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 8, Frequency, 2=Occasionally | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 8, Frequency, 3=Frequently | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 15, Severity, 1=Mild | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 2 Day 15, Severity, 2=Moderate | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 15, Frequency, 1=Rarely | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 15, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 1, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 1, Frequency, 2=Occasionally | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 15, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Pre-IDS Evaluation, Frequency, 0=Never | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Pre-IDS Evaluation, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Pre-IDS Evaluation, Severity, 1=Mild | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Pre-IDS Evaluation, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Pre-IDS Evaluation, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Pre-IDS Evaluation, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, End Of Treatment, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Baseline, Severity, 2=Moderate | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Baseline, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 1 Day 8, Severity, 1=Mild | 10 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 1 Day 15, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 2 Day 15, Severity, 0=None | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, End Of Treatment, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, End Of Treatment, Frequency, 2=Occasionally | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 1, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 1, Frequency, 1=Rarely | 8 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 8, Frequency, 0=Never | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 15, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 15, Frequency, 0=Never | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 15, Frequency, 2=Occasionally | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 1, Severity, 1=Mild | 8 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 8, Severity, 0=None | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 8, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 15, Frequency, 0=Never | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 15, Frequency, 1=Rarely | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 15, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Pre-IDS Evaluation, Severity, 1=Mild | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, End Of Treatment, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 1 Day 15, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 2 Day 1, Frequency, 1=Rarely | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 2 Day 1, Frequency, 2=Occasionally | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 2 Day 1, Frequency, 3=Frequently | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 2 Day 1, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 2 Day 8, Frequency, 0=Never | 9 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 2 Day 8, Frequency, 1=Rarely | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 2 Day 8, Frequency, 2=Occasionally | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 2 Day 8, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 2 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 2 Day 15, Frequency, 0=Never | 12 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 2 Day 15, Frequency, 1=Rarely | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 2 Day 15, Frequency, 2=Occasionally | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 2 Day 15, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 1, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 8, Severity, 2=Moderate | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 8, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 8, Frequency, 2=Occasionally | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 15, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 15, Severity, 2=Moderate | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 15, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 1, Frequency, 2=Occasionally | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 15, Frequency, 1=Rarely | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 15, Frequency, 2=Occasionally | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 15, Frequency, 3=Frequently | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Cycle 3 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Pre-IDS Evaluation, Frequency, 0=Never | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Pre-IDS Evaluation, Frequency, 1=Rarely | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Pre-IDS Evaluation, Frequency, 2=Occasionally | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 3 Day 8, Frequency, 2=Occasionally | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Pre-IDS Evaluation, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 3 Day 8, Frequency, 3=Frequently | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 3 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 3 Day 15, Frequency, 0=Never | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 3 Day 15, Frequency, 1=Rarely | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 1 Day 8, Severity, 1=Mild | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 1 Day 8, Severity, 2=Moderate | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 1 Day 8, Severity, 3=Severe | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 1 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 3 Day 15, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Cycle 3 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, End Of Treatment, Severity, 0=None | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, End Of Treatment, Severity, 1=Mild | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Baseline, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Baseline, Severity, 1=Mild | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Baseline, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Baseline, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 1 Day 8, Severity, 0=None | 7 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 1 Day 8, Severity, 1=Mild | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 1 Day 8, Severity, 2=Moderate | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 1 Day 8, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 1 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 1 Day 15, Severity, 0=None | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 1 Day 15, Severity, 1=Mild | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 1 Day 15, Severity, 2=Moderate | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 1 Day 15, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 1 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 2 Day 1, Severity, 0=None | 8 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 2 Day 1, Severity, 1=Mild | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 2 Day 1, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 2 Day 8, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 2 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 2 Day 15, Severity, 0=None | 10 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 3 Day 1, Severity, 1=Mild | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 3 Day 1, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 3 Day 1, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 3 Day 8, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 3 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 3 Day 15, Severity, 0=None | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Cycle 3 Day 15, Severity, 1=Mild | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, Pre-IDS Evaluation, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, End Of Treatment, Severity, 0=None | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, End Of Treatment, Severity, 1=Mild | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, End Of Treatment, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, End Of Treatment, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs Tasting Food/Drink, End Of Treatment, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Baseline, Severity, 0=None | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Baseline, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Baseline, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 8, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 8, Severity, 1=Mild | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 8, Severity, 2=Moderate | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 8, Severity, 3=Severe | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 8, Frequency, 0=Never | 8 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 8, Frequency, 1=Rarely | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 8, Frequency, 2=Occasionally | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 8, Frequency, 3=Frequently | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 8, Frequency, 4=Almost constantly | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 15, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, Pre-IDS Evaluation, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, End Of Treatment, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, End Of Treatment, Severity, 1=Mild | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Baseline, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Baseline, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Baseline, Frequency, 0=Never | 16 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 8, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 8, Severity, 1=Mild | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 8, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 8, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 8, Frequency, 0=Never | 12 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 8, Frequency, 1=Rarely | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 1 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 1, Severity, 0=None | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, End Of Treatment, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, End Of Treatment, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, End Of Treatment, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 1, Frequency, 2=Occasionally | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 1, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 1, Frequency, 4=Almost constantly | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 8, Severity, 0=None | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 8, Severity, 1=Mild | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 8, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 8, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 8, Frequency, 0=Never | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 15, Severity, 1=Mild | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 15, Severity, 2=Moderate | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 15, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 15, Frequency, 0=Never | 8 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 15, Frequency, 1=Rarely | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 2 Day 15, Frequency, 2=Occasionally | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 1, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 1, Severity, 4=Very severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 1, Frequency, 0=Never | 8 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 1, Frequency, 1=Rarely | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 1, Frequency, 2=Occasionally | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 1, Frequency, 3=Frequently | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 1, Frequency, 4=Almost constantly | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 8, Severity, 0=None | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 8, Frequency, 3=Frequently | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 15, Severity, 0=None | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 15, Severity, 1=Mild | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 15, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 15, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Cycle 3 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Nausea, Pre-IDS Evaluation, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 8, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, End Of Treatment, Frequency, 0=Never | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Bloating of Abdomen, End Of Treatment, Frequency, 1=Rarely | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Pre-IDS Evaluation, Frequency, 2=Occasionally | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Baseline, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Baseline, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 1 Day 8, Severity, 0=None | 8 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 15, Frequency, 0=Never | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 15, Frequency, 2=Occasionally | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 15, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 1 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 1, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 1, Severity, 1=Mild | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 1, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 1, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 1, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 8, Severity, 1=Mild | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 8, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 8, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 8, Frequency, 0=Never | 9 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 8, Frequency, 1=Rarely | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 8, Frequency, 2=Occasionally | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 1 Day 8, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 2 Day 15, Frequency, 0=Never | 13 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 1, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 8, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 8, Severity, 1=Mild | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 8, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 8, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Cycle 3 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Pre-IDS Evaluation, Frequency, 2=Occasionally | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Vomiting, Pre-IDS Evaluation, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, End Of Treatment, Severity, 0=None | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, End Of Treatment, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 1 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 2 Day 1, Severity, 0=None | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, End Of Treatment, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Baseline, Severity, 0=None | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 1 Day 8, Severity, 1=Mild | 8 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 1 Day 8, Severity, 2=Moderate | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 1 Day 8, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 1 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 1 Day 15, Severity, 0=None | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 1 Day 15, Severity, 1=Mild | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 1 Day 15, Severity, 2=Moderate | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 1 Day 15, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 2 Day 1, Severity, 1=Mild | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 2 Day 1, Severity, 2=Moderate | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 2 Day 1, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 2 Day 8, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 2 Day 8, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 2 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 2 Day 15, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 2 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 3 Day 1, Severity, 0=None | 9 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 3 Day 1, Severity, 1=Mild | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 3 Day 1, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 3 Day 8, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 3 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 3 Day 15, Severity, 0=None | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Cycle 3 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 2 Day 1, Severity, 2=Moderate | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 2 Day 1, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 2 Day 1, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 2 Day 15, Severity, 0=None | 9 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 2 Day 15, Severity, 1=Mild | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 2 Day 15, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 2 Day 15, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 2 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 3 Day 1, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 3 Day 1, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 3 Day 8, Severity, 0=None | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 3 Day 8, Severity, 1=Mild | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 3 Day 15, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 3 Day 15, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Cycle 3 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Probs w/Concentration, Pre-IDS Evaluation, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Pre-IDS Evaluation, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 2 Day 8, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 2 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Pre-IDS Evaluation, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 3 Day 1, Severity, 0=None | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 3 Day 1, Severity, 2=Moderate | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 3 Day 1, Severity, 3=Severe | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 3 Day 1, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Pre-IDS Evaluation, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, Pre-IDS Evaluation, Severity, 4=Very severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, End Of Treatment, Severity, 0=None | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, End Of Treatment, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 3 Day 15, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 3 Day 15, Severity, 2=Moderate | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, End Of Treatment, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Problems w/Memory, End Of Treatment, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Baseline, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Baseline, Frequency, 1=Rarely | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Baseline, Frequency, 2=Occasionally | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Baseline, Frequency, 3=Frequently | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Baseline, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 8, Severity, 2=Moderate | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 8, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 8, Frequency, 3=Frequently | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 15, Severity, 1=Mild | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 15, Frequency, 0=Never | 8 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 15, Frequency, 1=Rarely | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 15, Frequency, 2=Occasionally | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 1 Day 15, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 1, Severity, 1=Mild | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 1, Severity, 2=Moderate | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 1, Frequency, 3=Frequently | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 3 Day 15, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 3 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 1, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 8, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 8, Severity, 1=Mild | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 8, Severity, 2=Moderate | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 8, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 15, Severity, 1=Mild | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 15, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 15, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 2 Day 15, Frequency, 0=Never | 7 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 1, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 1, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 1, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 1, Frequency, 0=Never | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 8, Frequency, 0=Never | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 8, Frequency, 1=Rarely | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 8, Frequency, 2=Occasionally | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 8, Frequency, 3=Frequently | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 8, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 15, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 15, Severity, 1=Mild | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 15, Frequency, 1=Rarely | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 15, Frequency, 2=Occasionally | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 15, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, Cycle 3 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, End Of Treatment, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, End Of Treatment, Frequency, 0=Never | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Pre-IDS Evaluation, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, End Of Treatment, Frequency, 1=Rarely | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Pre-IDS Evaluation, Severity, 1=Mild | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, End Of Treatment, Frequency, 2=Occasionally | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Muscles, End Of Treatment, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Pre-IDS Evaluation, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Pre-IDS Evaluation, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, End Of Treatment, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Baseline, Severity, 0=None | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Baseline, Severity, 1=Mild | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Baseline, Severity, 2=Moderate | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Baseline, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Baseline, Severity, 1=Mild | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Baseline, Severity, 4=Very severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Baseline, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Baseline, Frequency, 0=Never | 11 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Baseline, Frequency, 1=Rarely | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Baseline, Frequency, 2=Occasionally | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 8, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 8, Severity, 1=Mild | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Baseline, Frequency, 3=Frequently | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Baseline, Frequency, 4=Almost constantly | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 8, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 8, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 8, Frequency, 0=Never | 12 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 8, Frequency, 1=Rarely | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 8, Frequency, 2=Occasionally | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 8, Frequency, 4=Almost constantly | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 15, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 15, Severity, 1=Mild | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 15, Severity, 2=Moderate | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 15, Severity, 3=Severe | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 1 Day 15, Frequency, 0=Never | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 1 Day 15, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 1, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 1, Severity, 1=Mild | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 15, Frequency, 1=Rarely | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 15, Frequency, 2=Occasionally | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 2 Day 15, Frequency, 3=Frequently | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 1, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 1, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 1, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 1, Frequency, 0=Never | 8 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 1, Frequency, 1=Rarely | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 1, Frequency, 2=Occasionally | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 8, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 1, Frequency, 3=Frequently | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 8, Frequency, 0=Never | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 1, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 8, Frequency, 1=Rarely | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 8, Frequency, 2=Occasionally | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 15, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 8, Severity, 1=Mild | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 8, Severity, 2=Moderate | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 15, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Cycle 3 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 8, Frequency, 1=Rarely | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 8, Frequency, 2=Occasionally | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 8, Frequency, 3=Frequently | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Pre-IDS Evaluation, Frequency, 0=Never | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, Pre-IDS Evaluation, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, End Of Treatment, Severity, 0=None | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, End Of Treatment, Severity, 1=Mild | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 15, Severity, 1=Mild | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 15, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 15, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, End Of Treatment, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, End Of Treatment, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, End Of Treatment, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, End Of Treatment, Frequency, 0=Never | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, End Of Treatment, Frequency, 1=Rarely | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, End Of Treatment, Frequency, 2=Occasionally | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Aching Joints, End Of Treatment, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Baseline, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 1 Day 8, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 1 Day 8, Severity, 1=Mild | 7 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 1 Day 8, Severity, 2=Moderate | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 1 Day 8, Severity, 3=Severe | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 1 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Fatigue/Lack of Energy, Cycle 1 Day 15, Severity, 0=None | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Cycle 3 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Pre-IDS Evaluation, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Pre-IDS Evaluation, Severity, 1=Mild | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Pre-IDS Evaluation, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Pre-IDS Evaluation, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Pre-IDS Evaluation, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Pre-IDS Evaluation, Frequency, 0=Never | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Pre-IDS Evaluation, Frequency, 1=Rarely | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Pre-IDS Evaluation, Frequency, 2=Occasionally | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Pre-IDS Evaluation, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, Pre-IDS Evaluation, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, End Of Treatment, Severity, 0=None | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, End Of Treatment, Severity, 1=Mild | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, End Of Treatment, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, End Of Treatment, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Anxiety, End Of Treatment, Frequency, 0=Never | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Baseline, Severity, 4=Very severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Baseline, Frequency, 0=Never | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Baseline, Frequency, 1=Rarely | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Baseline, Frequency, 2=Occasionally | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Baseline, Frequency, 3=Frequently | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Baseline, Frequency, 4=Almost constantly | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 8, Severity, 0=None | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 8, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 8, Frequency, 4=Almost constantly | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 15, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 15, Severity, 1=Mild | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 15, Severity, 2=Moderate | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 15, Frequency, 1=Rarely | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 15, Frequency, 2=Occasionally | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 15, Frequency, 3=Frequently | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 1 Day 15, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 1, Severity, 0=None | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 1, Severity, 1=Mild | 7 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 1, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 8, Severity, 0=None | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 8, Severity, 1=Mild | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 8, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 8, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 15, Frequency, 1=Rarely | 7 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 2 Day 15, Frequency, 3=Frequently | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 1, Severity, 0=None | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 1, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 1, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 1, Frequency, 0=Never | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 1, Frequency, 1=Rarely | 9 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 1, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Cycle 3 Day 8, Severity, 1=Mild | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, Pre-IDS Evaluation, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, End Of Treatment, Severity, 0=None | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, End Of Treatment, Severity, 1=Mild | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, End Of Treatment, Severity, 2=Moderate | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, End Of Treatment, Frequency, 0=Never | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, End Of Treatment, Frequency, 1=Rarely | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, End Of Treatment, Frequency, 2=Occasionally | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Sad or Unhappy Feelings, End Of Treatment, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Pre-IDS Evaluation, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, Pre-IDS Evaluation, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, End Of Treatment, Frequency, 0=Never | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, End Of Treatment, Frequency, 1=Rarely | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, End Of Treatment, Frequency, 2=Occasionally | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Loose/Watery Stools, End Of Treatment, Frequency, 3=Frequently | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Baseline, Severity, 0=None | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Baseline, Severity, 1=Mild | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Baseline, Severity, 2=Moderate | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Baseline, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Baseline, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Baseline, Frequency, 0=Never | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Baseline, Frequency, 1=Rarely | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Baseline, Frequency, 2=Occasionally | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Baseline, Frequency, 3=Frequently | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Baseline, Frequency, 4=Almost constantly | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Pain in the Abdomen, Cycle 1 Day 8, Severity, 0=None | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Numb/Tingling Hands/Feet, Cycle 3 Day 15, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 1 Day 15, Severity, 1=Mild | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 1 Day 15, Severity, 2=Moderate | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 1 Day 15, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 1 Day 15, Severity, 4=Very severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 2 Day 1, Severity, 0=None | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 2 Day 1, Severity, 1=Mild | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 2 Day 1, Severity, 2=Moderate | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 2 Day 1, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 2 Day 1, Severity, 4=Very severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 2 Day 8, Severity, 0=None | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 2 Day 8, Severity, 1=Mild | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 2 Day 8, Severity, 2=Moderate | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 2 Day 8, Severity, 3=Severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 2 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 2 Day 15, Severity, 0=None | 8 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 2 Day 15, Severity, 1=Mild | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 2 Day 15, Severity, 2=Moderate | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 2 Day 15, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 2 Day 15, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 3 Day 1, Severity, 0=None | 6 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 3 Day 1, Severity, 1=Mild | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 3 Day 1, Severity, 2=Moderate | 5 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 3 Day 1, Severity, 3=Severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 3 Day 1, Severity, 4=Very severe | 1 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 3 Day 8, Severity, 0=None | 4 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 3 Day 8, Severity, 1=Mild | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 3 Day 8, Severity, 2=Moderate | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 3 Day 8, Severity, 3=Severe | 2 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 3 Day 8, Severity, 4=Very severe | 0 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 3 Day 15, Severity, 0=None | 3 Participants |
| Niraparib | Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Constipation, Cycle 3 Day 15, Severity, 1=Mild | 3 Participants |
Secondary
Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5
The FACT-GP5 item is a single item from the FACT-G that assesses how bothersome the side effects of treatment are for participants with cancer. It evaluates the extent to which side effects of treatment are bothersome for cancer participants. This outcome is measured using a 5-category response scale, where responses include 0=Not at all, 1=A little bit, 2=Somewhat, 3=Quite a bit, and 4=Very much. A higher score on this measure indicates that the participant experiences a greater level of bother from the side effects of treatment.
Time frame: Baseline (Predose), Day 8 and 15 of Cycle 1; Day 1, 8, and 15 of Cycle 2 and Cycle 3; Pre-IDS Evaluation, and End of Treatment (Up to approximately 154 weeks)
Population: Intent to Treat Population is included as the Overall Number of Participants Analyzed. 'Number Analyzed' refers to participants evaluable at the specified time points. The 0 participants analyzed represents that data was not collected or available for analysis at that particular time point for the respective Arms/Groups.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 1 Day 8, 3=Quite a bit | 6 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 3 Day 15, 0=Not at all | 0 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 1 Day 8, 4=Very much | 1 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 3 Day 15, 1=A little bit | 3 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 1 Day 15, 0=Not at all | 4 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 2 Day 8, 4=Very much | 2 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 1 Day 15, 1=A little bit | 2 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 3 Day 15, 2=Somewhat | 1 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 1 Day 15, 3=Quite a bit | 2 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 2 Day 1, 0=Not at all | 4 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 1 Day 15, 4=Very much | 2 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 3 Day 15, 3=Quite a bit | 1 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 2 Day 1, 4=Very much | 0 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 2 Day 1, 2=Somewhat | 2 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 3 Day 15, 4=Very much | 0 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 2 Day 8, 0=Not at all | 1 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Pre-IDS Evaluation, 0=Not at all | 2 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 2 Day 8, 2=Somewhat | 3 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 1 Day 15, 2=Somewhat | 4 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 2 Day 15, 0=Not at all | 2 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 3 Day 1, 4=Very much | 0 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 2 Day 15, 1=A little bit | 3 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 2 Day 8, 1=A little bit | 4 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 2 Day 15, 2=Somewhat | 5 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 3 Day 8, 1=A little bit | 3 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 2 Day 15, 3=Quite a bit | 2 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 2 Day 15, 4=Very much | 1 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Baseline, 0=Not at all | 4 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 3 Day 1, 0=Not at all | 1 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Baseline, 1=A little bit | 4 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 3 Day 1, 1=A little bit | 9 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 2 Day 1, 1=A little bit | 4 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 3 Day 1, 2=Somewhat | 4 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Baseline, 2=Somewhat | 1 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 3 Day 1, 3=Quite a bit | 0 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 3 Day 8, 0=Not at all | 1 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Baseline, 3=Quite a bit | 4 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 3 Day 8, 2=Somewhat | 0 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Baseline, 4=Very much | 1 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 2 Day 8, 3=Quite a bit | 1 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Pre-IDS Evaluation, 1=A little bit | 7 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Pre-IDS Evaluation, 2=Somewhat | 6 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 1 Day 8, 0=Not at all | 0 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Pre-IDS Evaluation, 3=Quite a bit | 0 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 3 Day 8, 3=Quite a bit | 5 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Pre-IDS Evaluation, 4=Very much | 0 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 1 Day 8, 1=A little bit | 2 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 3 Day 8, 4=Very much | 1 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 1 Day 8, 2=Somewhat | 2 Participants |
| Platinum-taxane | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 2 Day 1, 3=Quite a bit | 1 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Pre-IDS Evaluation, 3=Quite a bit | 0 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Pre-IDS Evaluation, 4=Very much | 0 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | End Of Treatment, 0=Not at all | 2 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | End Of Treatment, 1=A little bit | 1 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Baseline, 0=Not at all | 4 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | End Of Treatment, 4=Very much | 0 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Baseline, 2=Somewhat | 7 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 1 Day 15, 1=A little bit | 2 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 2 Day 1, 0=Not at all | 5 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 2 Day 1, 3=Quite a bit | 2 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 2 Day 1, 4=Very much | 0 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 2 Day 8, 1=A little bit | 3 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 2 Day 8, 3=Quite a bit | 0 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 2 Day 8, 4=Very much | 0 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 2 Day 15, 3=Quite a bit | 1 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 3 Day 1, 3=Quite a bit | 1 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 3 Day 1, 4=Very much | 0 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 3 Day 8, 1=A little bit | 3 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 3 Day 8, 2=Somewhat | 6 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 3 Day 8, 4=Very much | 0 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 3 Day 15, 1=A little bit | 2 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 3 Day 15, 2=Somewhat | 3 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 3 Day 15, 3=Quite a bit | 0 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Pre-IDS Evaluation, 0=Not at all | 2 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Pre-IDS Evaluation, 1=A little bit | 1 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | End Of Treatment, 2=Somewhat | 2 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | End Of Treatment, 3=Quite a bit | 0 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Baseline, 1=A little bit | 6 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Baseline, 3=Quite a bit | 0 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Baseline, 4=Very much | 0 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 1 Day 8, 0=Not at all | 2 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 1 Day 8, 1=A little bit | 5 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 1 Day 8, 2=Somewhat | 7 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 1 Day 8, 3=Quite a bit | 1 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 1 Day 8, 4=Very much | 0 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 1 Day 15, 0=Not at all | 5 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 1 Day 15, 2=Somewhat | 7 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 1 Day 15, 3=Quite a bit | 0 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 1 Day 15, 4=Very much | 0 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 2 Day 1, 1=A little bit | 2 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 2 Day 1, 2=Somewhat | 5 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 2 Day 8, 0=Not at all | 3 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 2 Day 8, 2=Somewhat | 6 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 2 Day 15, 0=Not at all | 4 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 2 Day 15, 1=A little bit | 5 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 2 Day 15, 2=Somewhat | 4 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 2 Day 15, 4=Very much | 0 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 3 Day 1, 0=Not at all | 4 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 3 Day 1, 1=A little bit | 3 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 3 Day 1, 2=Somewhat | 6 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 3 Day 8, 0=Not at all | 1 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 3 Day 8, 3=Quite a bit | 0 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 3 Day 15, 0=Not at all | 2 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Cycle 3 Day 15, 4=Very much | 0 Participants |
| Niraparib | Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5 | Pre-IDS Evaluation, 2=Somewhat | 4 Participants |
Secondary
Number of Participants With Treatment Emergent (TE) Non-serious Adverse Events (Non-SAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Adverse Events of Treatment Emergent (TE) Special Interest (AESIs) by Severity
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, is life threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, is a congenital anomaly/birth defect, other situations and is associated with liver injury or impaired liver function. SAEs are subsets of AEs. TEAE is an event that emerged during treatment having been absent pretreatment or worsened relative to the pretreatment state. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.
Time frame: Up to approximately 154 weeks
Population: Safety population included all randomized participants who received at least one dose of study treatment.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Platinum-taxane | Number of Participants With Treatment Emergent (TE) Non-serious Adverse Events (Non-SAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Adverse Events of Treatment Emergent (TE) Special Interest (AESIs) by Severity | TE Non-SAEs | 17 Participants |
| Platinum-taxane | Number of Participants With Treatment Emergent (TE) Non-serious Adverse Events (Non-SAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Adverse Events of Treatment Emergent (TE) Special Interest (AESIs) by Severity | TESAEs | 4 Participants |
| Platinum-taxane | Number of Participants With Treatment Emergent (TE) Non-serious Adverse Events (Non-SAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Adverse Events of Treatment Emergent (TE) Special Interest (AESIs) by Severity | TE AESIs | 0 Participants |
| Niraparib | Number of Participants With Treatment Emergent (TE) Non-serious Adverse Events (Non-SAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Adverse Events of Treatment Emergent (TE) Special Interest (AESIs) by Severity | TE Non-SAEs | 19 Participants |
| Niraparib | Number of Participants With Treatment Emergent (TE) Non-serious Adverse Events (Non-SAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Adverse Events of Treatment Emergent (TE) Special Interest (AESIs) by Severity | TESAEs | 2 Participants |
| Niraparib | Number of Participants With Treatment Emergent (TE) Non-serious Adverse Events (Non-SAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Adverse Events of Treatment Emergent (TE) Special Interest (AESIs) by Severity | TE AESIs | 0 Participants |
Secondary
Overall Survival (OS)
OS is defined as the time from the date of treatment randomization to the date of death by any cause.
Time frame: Up to approximately 154 weeks
Population: As pre-specified in Section 2 of the Statistical Analysis Plan, analyses was not performed due to low maturity (\<30%) for OS data, resulting from insufficient number of participants with events within the length of follow-up in assessing the number of events.
Secondary
Progression Free Survival (PFS)
PFS is defined as the time from the date of treatment randomization to the date of first documentation of disease progression (PD) per RECIST v1.1 or death by any cause, whichever occurs first, as determined by the Investigator. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm.
Time frame: Up to approximately 154 weeks
Population: As pre-specified in Section 2 of the Statistical Analysis Plan, analyses was not performed due to low maturity (\<30%) for PFS data, resulting from insufficient number of participants with events within the length of follow-up in assessing the number of events.
Secondary
Time to First Subsequent Treatment (TFST)
TFST is defined as the time from the date of treatment randomization to the date of first subsequent anticancer therapy or death.
Time frame: Up to approximately 154 weeks
Population: As pre-specified in Section 2 of the Statistical Analysis Plan, analyses was not performed due to low maturity (\<30%) for TFST data, resulting from insufficient number of participants with events within the length of follow-up in assessing the number of events.